Colleen S. Curran1*
Jeffrey B. Kopp2- 1Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD, United States
- 2Kidney Disease Section, NIDDK, NIH, Bethesda, MD, United States
The aryl hydrocarbon receptor (AHR) is a basic helix-loop-helix transcription factor that binds diverse endogenous and xenobiotic ligands, which regulate AHR stability, transcriptional activity, and cell signaling. AHR activity is strongly implicated throughout the course of chronic kidney disease (CKD). Many diverse organic molecules bind and activate AHR and these ligands are reported to either promote glomerular and tubular damage or protect against kidney injury. AHR crosstalk with estrogen, peroxisome proliferator-activated receptor-γ, and NF-κB pathways may contribute to the diversity of AHR responses during the various forms and stages of CKD. The roles of AHR in kidney fibrosis, metabolism and the renin angiotensin system are described to offer insight into CKD pathogenesis and therapies.
Introduction
Chronic kidney disease (CKD) affects approximately 37 million (1 in 7) US adults and is the ninth leading cause of death (CDC, 2020). The global incidence of CKD has been estimated at 13.7% (11.7–15.1%) of the nearly eight billion people, or over one billion cases. Current therapies may slow and occasionally halt CKD progression, but most patients continue to progress. Further, these therapies are not fully available to or fully used by many of the globally-affected individuals. CKD is accompanied by premature morbidity and mortality from cardiovascular disease, as hypertension and uremia combine to drive cardiac and vascular damage.
CKD can be caused by systemic diseases and by primary kidney diseases. CKD due to systemic disease is more common; causes include diabetes mellitus (Navaneethan et al., 2021), malignant hypertension (van den Born et al., 2005), systemic lupus erythematosus and systemic vasculitis (Moiseev et al., 2020). Primary kidney diseases, those that chiefly affect the kidney, include polycystic kidney disease, interstitial nephritis, and podocytopathies (minimal change disease, focal segmental glomerulosclerosis and membranous nephropathy) (Curran and Kopp, 2021).
Many CKD patients progress to end-stage kidney disease. Kidney transplant extends life for chronic dialysis patient by a median of 12 years (2014–2017: median 11.7 for deceased donor kidney recipients, median 12.1 years for living donor kidney recipients) (Poggio et al., 2020) and longer in some cases (Zolota et al., 2020). Many patients on chronic dialysis, particularly in the First World, are older and have co-morbidities; their 5-year survival rate has been reported as 56% (Nordio et al., 2012).
Increased rates of cardiovascular disease in CKD patients are the major driver of reduced survival (Jankowski et al., 2021). Thus, better strategies are needed to prevent CKD and to slow or halt progressive loss of kidney function in individuals with CKD.
CKD incidence is linked to several risk factors. Non-modifiable risk factors include genetic variants, low birth weight, and older age. Notable genetic variants include polymorphisms in angiotensin-I converting enzyme (ACE), angiotensin II type 1 receptor (AGTR1) and apolipoprotein L1 (APOL1), the latter accounting for much of the excess CKD risk among populations with sub-Saharan ancestry. Common modifiable risk factors include smoking, obesity, hypertension, diabetes mellitus, excessive alcohol consumption, heavy metal exposure, and excessive use of analgesic medicines (Kazancioglu, 2013). These factors compromise or alter kidney cell function, affecting cells in the glomerulus (podocytes, mesangial cells, and endothelial cells) and in the tubulo-interstitium (tubular cells, endothelial cells, and fibroblasts).
The various factors that induce CKD allow for the development of animal models to mimic the response. These can include 5/6 nephrectomy, unilateral ureteral obstruction nephropathy, angiotensin II (Ang II)-induced hypertension, ischemia/reperfusion-induced acute kidney injury, cisplatin- or cyclosporin A-induced nephropathy or models of systemic disease. An underlying factor in animal or human CKD progression is the aryl hydrocarbon receptor (AHR). This nuclear receptor is activated by endogenous and exogenous ligands and is required for normal kidney development and function. In cultures of murine metanephros, the AHR ligand, benzo(a)pyrene (BaP), disrupted nephrogenesis (Falahatpisheh and Ramos, 2003) and in fetuses from mice fed the AHR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin), hydronephrosis was a common malformation (Peters et al., 1999). AHR renal mRNA levels were also higher in female rats compared to males and at 7 weeks post-5/6 nephrectomy, AHR renal mRNA levels decreased in females, but not males, highlighting a role for AHR in renal gender differences (Lu et al., 2006).
In an animal model of CKD, AHR is not only activated in the kidney but additional organs. Specifically, transgenic mice expressing the AHR responsive-promoter tethered to a β-galactosidase reporter gene and subjected to ischemia/reperfusion-induced acute kidney injury identified AHR activation in the proximal and distal renal tubules, cardiac myocytes, hepatocytes, and microvasculature in the cerebral cortex (Walker et al., 2020). This suggests a presence of AHR ligands in serum, which can activate cells in the kidney, heart, brain, and liver. By culturing serum with an AHR reporter cell line, elevated AHR activity was identified in diabetic nephropathy patients compared to controls (Kim et al., 2013). Serum levels of the AHR ligand, indole-3 acetic acid, measured as a predictor of cardiovascular events and mortality in 120 CKD patients with stage 3–5 CKD and stage 5D CKD (Dou et al., 2015). Indole-3 acetic acid (Lin et al., 2019) and another AHR ligand, indoxyl sulfate (Yeh et al., 2016), are additionally associated with cognitive impairments in CKD patients. The gut is the source of indole, which is processed in the liver to indoxyl sulfate, highlighting AHR ligand crosstalk between organs and within the liver (Lowenstein and Nigam, 2021).
The heterogeneity of CKD presentation and progression may be associated with the diversity of AHR ligands that promote and inhibit disease. As shown in Table 1, select AHR compounds that promote kidney injury include non-steroidal anti-inflammatory drugs (NSAIDs), tryptophan metabolites, bacterial pigments, proton pump inhibitors, certain antibiotics, and polycyclic aromatic hydrocarbons (PAHs). Select AHR compounds that inhibit kidney injury include quinoline derivatives, dietary compounds (e.g., resveratrol, indole-3-carbinol), and the tryptophan photo-oxidation product, 6-formylindolo (3,2-b) carbazole (FICZ). The uremic solutes, which include tryptophan metabolites (e.g., indoxyl sulfate, indole-3-acetic acid), contribute to increased vascular permeability, vessel leakage and inflammation (Falconi et al., 2021). The mechanisms may involve indoxyl sulfate-induced endothelial adhesion molecules, which bind to and recruit leukocytes as shown in vitro (Ito et al., 2016). In addition, the AHR antagonist, resveratrol, blocked indoxyl sulfate-induced bovine aorta endothelial cell permeability in vitro (Assefa et al., 2019), further supporting a function of AHR in CKD pathogenesis.
TABLE 1. Function of select AHR ligands in chronic kidney disease.
Independent of the inciting cause of kidney damage, subsequent progression of CKD is associated with metabolic disturbances, oxidative stress, and inflammation, all of which promote fibrogenesis, irreversible nephron loss, and ultimately reduce the glomerular filtration rate (Ruiz-Ortega et al., 2020). Reduced kidney function leads to the retention of various metabolic products, particularly nitrogenous compounds and often excess fluid, sodium, potassium and phosphate, among many small molecules. These metabolic alterations are characteristic of uremia, and some of these in turn, promote cardiovascular disease (Ghoshal and Freedman, 2019).
Fibrosis in CKD
Tissue damage from injury or disease induces tissue remodeling and repair. Dysregulation of this process causes an imbalance in extracellular matrix (ECM) homeostasis and the formation of fibrotic tissue. Kidney interstitial ECM consists of diverse molecules, of which the principal families are collagen (types I, II, III, V, VI, VII, and XV), glycoproteins (e.g., fibronectin, laminin), proteoglycans (e.g., biglycan, decorin, versican) and glycosaminoglycans (e.g., chondroitin sulfate, dermatan sulfate, heparin sulfate, hyaluronan). Collectively, these molecules anchor cells within tissue (Bulow and Boor, 2019).
The human genome encodes three isoforms of TGF-β (TGF-β1, TGF-β2, TGF-β3). With regard to extracellular matrix biology; all three isoforms may promote collagen production and tissue fibrosis (Curran and Keely, 2013; Sun T. et al., 2021; Panizo et al., 2021). Activated inflammatory cells secrete inactive TGF-β1 bound non-covalently to a latency associated peptide (LAP), which is disulfide bound to the latent TGF-β binding protein (LTBP). Tissue transglutaminase-2 binds the released complex of LTBP:LAP:TGF-β1 to the ECM by enzymatically cross-linking LTBP to fibronectin and possibly additional ECM proteins associated with elastic fibers (Nunes et al., 1997). Active TGF-β1 is released from the large latent complex by integrin-mediated mechanical deformation of the ECM and/or through degradation of LAP by proteases (e.g., MMPs, thrombospondin-1, and plasmin) (Curran and Keely, 2013).
Intracellular signals downstream from the TGF-β1 receptor stimulate interstitial myofibroblast proliferation and secretion of collagen and additional ECM proteins (Panizo et al., 2021), promote anaerobic metabolism (Zhao et al., 2020), regulate immune cell differentiation (Sanjabi et al., 2017), and induce the expression of integrins (Curran and Keely, 2013) and the nuclear factor-kappa-B (NF-κB) subunit, p65 (Sun et al., 2015). Peroxisome proliferator-activated receptor-gamma (PPAR)-γ ligands (Guo et al., 2004), estrogen (Ito et al., 2010), and AHR ligands (Woeller et al., 2016; Shi et al., 2020) antagonize TGF-β1 cell signaling. The expression of TGF-β1 is induced by hypoxia (Mingyuan et al., 2018), angiotensin II (Kagami et al., 1994), cytokines (interleukin (IL)-4, IL-13), advanced glycation end products (AGEs) (Li et al., 2004), and autocrine cell signals (Bhogal et al., 2005). These factors are therefore likely to contribute to fibrogenesis in CKD.
With respect to AHR, the quinoline-3-carboxamide derivative and AHR ligand, paquinimod, inhibits fibrosis in murine models of experimental systemic sclerosis (Stenstrom et al., 2016) and liver fibrosis (Fransen Pettersson et al., 2018). The anti-fibrotic functions of paquinimod in CKD have not been significantly explored. Mice fed a diet supplemented with 0.25% adenine generate increased levels of the AHR ligand, indoxyl sulfate, comparable to human CKD patients, leading to periglomerular fibrosis (Walker et al., 2020). These data are supported in rats administered 200 mg/kg indoxyl sulfate drinking water, resulting in the elevated expression of the mesenchymal marker, α-smooth muscle actin, and increased Masson’s trichrome-positive fibrosis in the kidney (Bolati et al., 2011). Indoxyl sulfate induces TGF-β1 expression and production in human proximal tubular cells (HK-2 cells) and the antioxidant, indole-3-propionic acid, suppresses this response (Yisireyili et al., 2017). The indole acetic acid derivative, mitochonic acid 5 (MA-5), inhibits mitochondrial reactive oxygen species and improves renal function in an ischemia-reperfusion injury model and a cisplatin–induced nephropathy model (Suzuki et al., 2016). Moreover, mice administered MA-5 through osmotic pump in a model of unilateral ureteral obstruction demonstrated reduced expression of TGF-β1, decreased collagen I staining, and reduced renal fibrosis (Shima et al., 2017). Because dioxin-induced AHR promotes mitochondrial reactive oxygen species production and in AHR deficient mice, cellular mitochondrial reactive oxygen species are lower compared to controls (Brinkmann et al., 2019), the type of ligand and presence of AHR are likely important to oxidative stress in CKD.
Oxidative stress is associated with the activity of lysyl oxidases (LOX) (Martinez-Revelles et al., 2017) and transglutaminases (Basso et al., 2012), which promote vascular stiffness and neuronal death in murine models, respectively. These pleotropic proteins are involved in cell signaling and post-translational modifications, including the cross-linking of collagen. Calcium-dependent transglutaminases catalyze protein cross-links by introducing glutamyl-lysyl isopeptide bonds between target proteins. LOX catalyzes the formation of aldehydes from lysine residues in collagen and elastin, and this promotes cross-linking of these molecules in tissue (Heck et al., 2013). Transglutaminase-2 and LOX expression are induced by hypoxia and TGF-β (Curran and Keely, 2013), indicating that these molecules facilitate increased cross-linking and fibrosis in tissues with a compromised blood supply.
Excessive ECM accumulation is prevented by the activity of matrix metalloproteinases (MMPs), which cleave fibrillar collagens (Zhao et al., 2020). The AHR ligands FICZ (Shi et al., 2020), kynurenine (Li et al., 2014) and dioxin (Tsai et al., 2014) promote MMP-1 in vitro. The AHR ligand indole-3-carbinol inhibits MMP-2 and MMP-9 in vitro (Wu et al., 2005) and in a murine model of liver fibrosis, the AHR ligand paquinimod reduced the expression of MMP-2 (Fransen Pettersson et al., 2018), highlighting the diversity of the AHR response in ECM maintenance. Increased production and deposition of type I collagen, primarily by fibroblasts, is associated with increased transglutaminase-2 activity, promoting the formation of a stiff matrix; this can progress to overt kidney fibrosis (Bulow and Boor, 2019; Zhao et al., 2020).
In a study of 202 kidney disease cases of different etiologies, the levels of serum LOX and tissue LOX in renal biopsies were associated with the presence and degree of kidney fibrosis across diseases (Zhang XQ. et al., 2020). In cyclosporin A-induced nephropathy in mice, treatment with LOX inhibitors attenuated inflammation, fibrosis and uremia (Nguyen et al., 2021). Additionally, rats undergoing 5/6-nephrectomy and treated with transglutaminase inhibitors prevented a decline in kidney function and interstitial fibrosis (Johnson et al., 2007), highlighting these cross-linkers as targets in CKD. A role for AHR in regulating these cross-linkers through MMP production or oxidative responses has not been significantly explored.
CKD Therapies
Treatment of CKD involves several approaches. Treating the underlying disease, including systemic diseases (diabetes mellitus, systemic lupus, systemic vasculitis, and others), may slow or halt progression (Moiseev et al., 2020; Navaneethan et al., 2021). For example, the sodium-glucose transport protein 2 (SGLT2) inhibitor dapgliflozin was recently approved for progressive non-diabetic kidney disease of many etiologies as a result of studies demonstrating efficacy in reducing the risk for a combined endpoint of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure (Wheeler et al., 2021). Pathway-targeted treatments are increasingly available or in development for primary renal diseases or syndromes (e.g., focal segmental glomerulosclerosis, membranous nephropathy, and polycystic kidney disease) (Curran and Kopp, 2021; Finnigan and Leslie, 2021). At the other end of the frequency scale, there are an estimated 10,000 rare diseases (Haendel et al., 2020) and an unknown fraction of these have renal manifestations; many of these lack targeted therapies.
Non-specific therapies for CKD can slow and even halt progressive loss of kidney function. These include diet and medications for blood pressure control (target <130/80) (Faqah and Jafar, 2011), antifibrotic therapies (inhibitors of renin, angiotensin II, and aldosterone, the latter being a potent profibrotic molecule) (Zhang et al., 2019), and dietary sodium restriction and thiazide diuretics (the latter potentiates the antiproteinuric effects of the renin-angiotensin-aldosterone system antagonists) (Park et al., 2014). SGLT2 inhibitors reduce progression of kidney damage in diabetes (Tuttle et al., 2021) and recently this effect has been shown in non-diabetic kidney disease as well, possibly by reducing proximal tubule stress (Almaimani et al., 2021).
There continues to be considerable interest in developing novel anti-fibrotic therapies for kidney disease, although progress has been slow. Pirfenidone is an anti-fibrotic agent (2014 U.S. FDA approval reference ID: 3642437) that showed efficacy in phase two trials for idiopathic pulmonary fibrosis (Raghu et al., 1999; Maher et al., 2020). Preliminary studies of pirfenidone in studies of focal segmental glomerulosclerosis (Cho et al., 2007) and in diabetic nephropathy (Sharma et al., 2011) were encouraging but further development appears to have stalled. The exact mechanisms of action of pirfenidone are not fully characterized. Recent studies suggest the molecule may be a ligand for peroxisome proliferator-activated receptors (e.g., PPAR-α, PPAR-γ) (Hamidi et al., 2021), which appears to inhibit transforming growth factor (TGF)-β1-induced collagen I production (Cui et al., 2020). Pirfenidone may also suppress other profibrotic and pro-inflammatory mediators, including fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) (Chaudhary et al., 2007), interleukin-1β (IL-1β) and tumor necrosis factor (TNF) (Evani et al., 2020).
Similarly, ligands of the aryl hydrocarbon receptor (AHR), specifically tryptophan metabolites [e.g., 2-(10 H-indole30-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and FICZ], are capable of inhibiting TGF-β1-induced collagen I production in models of systemic sclerosis and thyroid eye disease (Woeller et al., 2016; Shi et al., 2020). An analog (SZR72) of kynurenic acid, a tryptophan metabolite and AHR ligand, inhibits the production of TNF in human blood cultures (Balog et al., 2021). Also, the plant-derived AHR ligand, indole-3-carbinol (I3C), antagonizes IL-1β production in cell lines (Jiang et al., 2013). AHR expression is induced by growth factors (PDGF, FGF) (Vaziri et al., 1996) and in a murine model of cardiac hypertrophy, AHR antagonizes hypoxia-induced VEGF production and the development of fibrosis (Ichihara et al., 2019). These functions of AHR suggest that AHR may be a therapeutic target in CKD. However, the AHR response is defined by a diverse array of toxins, endogenous molecules, drugs, dietary components, and pathogens that may promote or inhibit CKD (Table 1). AHR may additionally exhibit crosstalk with estrogen receptors, PPAR-γ, NF-kB, and cell signals in hypoxia and TGF-β1 pathways. In this regard, AHR has shown considerable, and puzzling, diversity of function in the kidney and manifestations associated with CKD. The effects of AHR in cell signaling pathways that influence fibrosis, the renin angiotensin aldosterone system (RAAS), and metabolism are therefore herein described.
AHR Stability, Signaling, and E3 Ubiquitin Ligase Activity
AHR is a ligand-activated transcription factor and E3 ubiquitin ligase with pleotropic functions in mammalian biology. Sequence homology between circadian [period (PER)] and neurodevelopment (single-minded (SIM) genes in Drosophila melanogaster and a gene in the human dioxin signaling pathway (AHR nuclear translocator (ARNT)) established the PER-ARNT-SIM (PAS) domain protein superfamily, of which AHR is a member. PAS domains mediate protein-protein and small-molecule-protein interactions. These include AHR dimerization with ARNT and AHR binding interactions with chaperone proteins and ligands (McIntosh et al., 2010).
Inactive AHR exists in the cytosol in a multi-protein complex, which includes a heat shock protein-90 (Hsp90) dimer, a co-chaperone (p23), an AHR interacting protein (AIP/XAP2/ARA9), and various co-activators, including members of Src family of non-receptor tyrosine kinases (Avilla et al., 2020). AIP (Lees et al., 2003) and p23 (Pappas et al., 2018) block ubiquitination of AHR, possibly by inhibiting AHR binding interactions with the E3 ubiquitin ligase C-terminal hsp70-interacting protein (STUB1/CHIP) (Morales and Perdew, 2007). E3 ubiquitin ligases provide a platform for ubiquitin enzymes to transfer ubiquitin to proteins. Ubiquitin binding can either alter protein signaling or target the protein to the proteasome for degradation (Buetow and Huang, 2016). Both ligand-bound and unliganded AHR can be targeted to the proteasome for degradation (Ma and Baldwin, 2000; Morales and Perdew, 2007).
Ligand binding to AHR in the multi-protein complex induces conformational changes in AHR and reorganization of the chaperones to facilitate nuclear localization of the complex (Avilla et al., 2020). AHR activation induces Src kinase phosphorylation (Xie et al., 2012) and cell signals that promote the production of IL-10 (Zhu et al., 2018). Release of active AHR from the complex allows AHR to partner with ARNT, which can also either dimerize with and activate hypoxia inducible transcription factors (HIFs) or the AHR repressor (AHRR). HIFs compete with AHR for ARNT dimerization and promote transcription of genes expressing enzymes in the glycolytic pathway (Goda and Kanai, 2012). AHR-induced AHRR not only competes with AHR for ARNT but also suppresses AHR function as a transcription factor by binding AHR responsive elements (AHREs) (Avilla et al., 2020) (Figure 1).
FIGURE 1. AHR-initiated cell signaling pathways. (1) The aryl hydrocarbon receptor (AHR) forms a complex with chaperone molecules in the cytoplasm. Ligand binding may promote transport of the complex into the nucleus. Alternatively, release of AHR from the complex may promote interactions with an E3 ligase (e.g., STUB1) which acts as a platform for AHR ubiquitination and targeted degradation via the proteasome. Both ligand-bound and unliganded AHR can be targeted to the proteasome. (2) AHR dissociates from its cytoplasmic complex to bind the AHR nuclear translocator (ARNT), which alternatively may dimerize with hypoxia inducible transcription factors (HIFs). AHR induces activation of signal-transducer and activator of transcription (STAT3) through Src signaling, acting as a tyrosine protein kinase involved in the production of IL-10. (3) AHR promotes the expression of the AHR repressor (AHRR), which also dimerizes with ARNT and negatively regulates AHR functions by competing with AHR binding sites in DNA regulatory sequences. (4) Activation of AHR or HIFs induces transcription and translation of PARP7 (poly ADP-ribosyl transferase 7), also known as TIPARP (TCDD-inducible poly-ADP-ribose polymerase). TIPARP further promotes polyADP-ribosylation and subsequent degradation of AHR and HIFs (5) Downstream responses of AHR can include activation of the biotransformation enzymes, including cytochrome P450 enzymes (P450s), UDP-gluconosyltransferases (UGTs), and ATP-binding cassette transporters (ABCs). Downstream responses of HIFs can include increased glycolysis and the expression of immunomodulatory genes that provoke inflammation.
AHR in Drug Metabolism
AHR has a pivotal role in regulating the clearance of xenobiotics and particular endogenous compounds (e.g., metabolites of tryptophan, arachidonic acid and hemoglobin), which also bind and activate AHR during various processes, including development (Avilla et al., 2020), hematopoiesis (Angelos and Kaufman, 2018) and disease pathogenesis (Curran et al., 2018; Curran et al., 2019). In the clearance of these molecules, the AHR:ARNT heterodimer induces the expression of proteins involved each of the three metabolic biotransformation pathways. These proteins neutralize the activity of endogenous and xenobiotic molecules and promote the efflux of these molecules from the cell (Figure 2).
FIGURE 2. AHR-initiated biotransformation. AHR induces the transcription of certain genes whose products are involved in each of the three phases of drug metabolism.
Phase I metabolism includes oxidation, reduction and hydrolysis of substrates, to generate more water-soluble, but generally still active, xenobiotic molecules (Phang-Lyn and Llerena, 2021). AHR-induced cytochrome P450 enzymes are a common measure of AHR activation in the liver. Their relevance in the kidney (Knights et al., 2013) and the immune system (Effner et al., 2017) are subjects of on-going study. Cytochrome P450 enzymes oxidize substrates and therefore contribute to phase I metabolism (Zanger and Schwab, 2013).
Phase II metabolism is carried out by conjugating enzymes, which add a hydrophilic group to targeted molecules; these protein modifications include glucuronidation, sulfation, acetylation, and methylation (Phang-Lyn and Llerena, 2021). UDP-gluconosyltransferase (UGT)-1A5, UTG1A6, UGT1A7, UGT1A9, UGT2B4, UGT2B4, and UGT2B17 are expressed in the kidney (Knights et al., 2013). AHR can induce UGT1A1 (Yueh et al., 2005) and UGT1A6 (Bock and Bock-Hennig, 2010) in human cell lines.
Phase III metabolism includes ATP-binding cassette (ABC) and solute carrier (SLC) transporters that facilitate xenobiotic efflux (Phang-Lyn and Llerena, 2021). Exposing rat brain capillaries to the AHR ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin), induced production of the ABC transporter, P-glycoprotein, also known as multidrug resistance protein (MRP)-1 (Wang et al., 2011). P-glycoprotein and additional ABC transporters [e.g., MRP2, MRP4, breast cancer resistance protein (BCRP)] are also induced in dioxin exposed killifish renal proximal tubules (Mahringer et al., 2019). Further testing of these responses in human kidney cells would enhance our knowledge of AHR kidney function.
AHR Function in ADP-Ribosylation
Both activated AHR (MacPherson et al., 2013) and HIF-1α (Zhang L. et al., 2020) promote transcription of the TCDD-inducible poly(ADP-ribose) polymerase (TIPARP/PARP7/ARTD14) gene. Poly-ADP-ribose polymerases (PARPs) post-translationally add a single ADP-ribosyl group (mono-ADP-ribosylation/MARylation) or multiple groups (poly-ADP-ribosylation/PARylation) to substrates (e.g., protein, DNA, and RNA) in regulating DNA repair, transcription, and cell signaling (Sanderson and Cohen, 2020). While the functional attributes of PARPs continue to be characterized, TIPARP uniquely is capable of negatively regulating its transcriptional activators (AHR, HIF-1α) (Figure 1). The mechanisms appear to involve TIPARP co-localization with the particular transcription factor and the recruitment of an E3 ligase for ubiquitin-mediated proteasome degradation of the transcription factor (MacPherson et al., 2013; Zhang L. et al., 2020). These integrated networks involving AHR and HIFs implicate AHR in basic metabolic processes and hypoxic responses during the development and progression of diseases such as CKD (Fu et al., 2016).
AHR Regulatory Mechanisms in CKD Signaling Networks
CKD manifests hypertension (Panizo et al., 2021), progressive kidney fibrosis (Bulow and Boor, 2019), and tissue hypoxia (Fu et al., 2016). Biochemical features include increased circulating plasma levels of extracellular nicotinamide phosphoribosyltransferase (eNAMPT/visfatin) (Hsu et al., 2016) and elevated blood levels of kynurenine (Cheng et al., 2020) (Figure 3). These pathologic processes and biomarkers are regulated by the RAAS, TGF-β1 cell signals, and metabolism. The roles of AHR in each of these systems is yet to be fully characterized.
FIGURE 3. Networks in CKD pathogenesis. TGF-β1 pathway: TGF-β1 signaling is initiated through serine/threonine kinase receptors, TGF-β1 receptor (TβR)-I and TβRII. TGF-β binding to TβRII recruits TβRI to form a receptor heterodimer, which is phosphorylated. SMAD2 and SMAD3 are recruited to the receptor heterodimer and are also phosphorylated. SMAD2 and SMAD3 co-localize with SMAD4 and translocate to the nucleus to activate genes, such as collagen and TGF-β1. ACE2 activity promotes the production of SMAD7, potentially via Ang-(1–7)-induced Mas or AT2R receptor signals. SMAD7 is a negative regulator of TGF-β1 by recruiting E3 ligases to TβRI and blocking TβRI-induced SMAD2/3 phosphorylation. Ligand activated AHR antagonizes TGF-β1 and collagen gene expression and protein production, which are associated with fibrosis. Ligand activated AHR also induces the degradation of collagen through the production of matrix metalloproteinase-1 (MMP1). Renin angiotensin aldosterone system (RAAS): Angiotensin I (Ang I) is cleaved by angiotensin converting enzyme (ACE) into Ang II. The binding of Ang II to AT1R or AT2R promotes the stable expression of HIF-1α and hypoxic responses. The ACE homolog, ACE2, inactivates Ang II by cleaving and processing Ang I and Ang II into Ang-(1–7), which is a ligand for the Mas receptor and AT2R. AHR regulates the expression of ACE2 and Mas. AT2R activation promotes TβRII degradation, inhibiting TGF-β1 signals. NAD de novo biosynthesis pathway (also known as the kynurenine pathway): Tryptophan catabolism is the defining feature of this pathway. The rate limiting enzymes are indoleamine dioxygenase (IDO) and tryptophan dioxygenase (TDO). IDO1 is induced by AHR:ARNT transcriptional activation of the IDO promoter and promotes the production of kynurenine, which can be released as a cytokine. A series of additional enzymes (highlighted in white) catalyze the production of immunomodulatory and neuroregulatory molecules that are further processed into NAD. Anaerobic metabolism: The production of adenosine triphosphate (ATP) in the absence of oxygen occurs through enzymatic reactions in glycolysis and results in the production of lactate and the increased formation of NADH relative to NAD. Enzymes in this pathway are regulated by HIF-1α activated genes (highlighted in orange), which can be stabilized by the RAAS. NAD salvage pathway: The primary source of mammalian NAD is from the recycling nicotinamide, which is the amide version of vitamin B3 and a by-product from the enzymatic activity of Poly-ADP-ribose polymerases (PARPs) and sirtuins. The rate limiting enzyme is nicotinamide phosphoribosyltransferase (NAMPT), which is transcriptionally activated by HIF-2α and functions as an extracellular cytokine. Indicators of disruption in homeostasis: Factors and conditions along these pathways are induced during CKD pathogenesis.
RAAS and AHR
The RAAS pathway involves a series of enzymatic reactions that contribute to the homeostatic control of extracellular fluid volume, arterial pressure, tissue perfusion, electrolyte balance, and wound healing. Renin, released from glomerular juxtaglomerular cells, processes liver-produced angiotensinogen into angiotensin I (Ang I), which is further cleaved by a soluble ectoprotein, angiotensin converting enzyme (ACE), into Ang II. The binding of Ang II to the Ang II type 1 receptor (AT1R) promotes vasoconstriction and also induces the production of aldosterone, which promotes renal tubular sodium reabsorption and promotes fibrogenesis. The ACE homolog, ACE2, inactivates Ang II by cleaving and processing Ang I and Ang II into Ang (1–7), which binds the Mas receptor and the AT2R. By these activities, ACE2 antagonizes the vasoconstrictive, inflammatory, prothrombotic, and fibrotic effects associated with ACE/Ang II/AT1R activity (Curran et al., 2020).
The functions of AHR in the RAAS signaling pathways appear to depend upon the level of expression of AHR and the AHR ligand. AHR-deficient mice develop cardiac hypertrophy through mechanisms involving HIF-1α cell signals (Thackaberry et al., 2002), Ang II-induced fibrosis (Ichihara et al., 2019), increased plasma levels of endothelin-1, and elevated mean arterial pressures (Lund et al., 2003). In heterozygous AHR (+/−) mice, blood pressure remains normal, and AHR (+/−) mice are more responsive to ACE inhibition and an endothelin-1 receptor antagonist compared to AHR (−/−) null mice (Zhang et al., 2010).
The effects of overexpression of AHR on RAAS activity have not been extensively examined. AHR overexpression in adipocytes shortens the half-life of PPAR-γ by recruiting PPAR-γ to the cullin 4b (CUL4B)-RING E3 ubiquitin ligase complex (Dou et al., 2019), leading to PPAR-γ degradation in the proteasome. Because reduced PPAR-γ activity induces AT1 expression and signaling in human fibroblasts (Auclair et al., 2013), overexpression of AHR may also affect the ACE/Ang II/AT1R pathway. Estrogen receptor (ER)-α can also be recruited by AHR to the CUL4B-RING E3 ubiquitin ligase complex resulting in ubiquitination (Luecke-Johansson et al., 2017) or targeted by TIPARP ADP-ribosylation (Zhang L. et al., 2020). These post-translational modifications that promote ER-α proteasome degradation indicate a potential role of AHR in sex-related differences in RAAS activity (Sabbatini and Kararigas, 2020) (Figure 4).
FIGURE 4. AHR degradative functions. AHR participates in the cullin/RING ubiquitin ligase (CRL-type E3 ligase) complex involving chaperones [e.g., cullin 4b (CUL4B)] to promote ubiquitination of estrogen receptor (ER)-α or peroxisome proliferator-activated receptor (PPAR)-γ. Activation of AHR or HIFs induces transcription and translation of PARP7 (poly ADP-ribosyl transferase 7), also known as TIPARP (TCDD-inducible poly-ADP-ribose polymerase). TIPARP promotes polyADP-ribosylation and subsequent degradation of ER-α.
Various AHR ligands increase in abundance during CKD pathogenesis and may affect RAAS activity. Reduced kidney function causes blood retention of a heterogeneous mix of metabolites (uremic solutes), which may be more effectively removed by continuous ambulatory peritoneal dialysis compared to low-flux hemodialysis (Xie et al., 2019). Tryptophan metabolites are uremic solutes and are AHR ligands, which promote CKD progression (Table 1). In a small study of CKD patients, an increased ratio of the tryptophan metabolite, kynurenine, to tryptophan was associated with macroalbuminuria and responsiveness to AT1R blockers (ARBs) (Wu et al., 2020). This study suggests upregulation of the ACE/Ang II/AT1R pathway in these individuals. However, in vitro examination of kynurenine-exposed BEAS-2B lung epithelial cells revealed AHR-induced production of ACE2 (Lv et al., 2021).
Because ACE2 activity antagonizes ACE/Ang II/AT1R cell signaling (Curran et al., 2020), additional factors in the RAAS pathway may be affected by AHR. One such factor is the Mas receptor. In normotensive and hypertensive rats, oral administration of the uremic solute, indoxyl sulfate, reduced kidney Mas receptor expression. This study further demonstrated that indoxyl sulfate-exposed human kidney-2 (HK-2) proximal tubular cells reduced Mas receptor expression and this response was antagonized by Ang-(1–7) pre-treatment or by the absence of AHR (Ng et al., 2014). Thus, AHR expression and activation are integral to the RAAS homeostatic function.
Metabolism and AHR
Ischemia and oxidative stress induce metabolic stressors (e.g., hypoxia) and the production of pro-inflammatory mediators (e.g., IL-1β, TNF, IL-6) during the progression of CKD. In a comprehensive pathway map analysis of gene sets from 157 European patients with nine different types of CKD, metabolism and inflammation were identified as the two main pathways in the pathology leading to CKD progression (Stenvinkel et al., 2021). Transcription factors, such as NF-κB and HIFs, regulate these responses and exhibit crosstalk with AHR.
There are three isoforms of HIF-α: HIF-1α, HIF-2α, and HIF-3α, encoded by distinct genes: HIF1A, EPAS1, HIF3A. HIF-1α and HIF-2α are expressed in the kidney, compete with AHR for the dimer partner ARNT, and can be degraded in either the proteasome or the lysosome (Hubbi et al., 2013; Jochmanova et al., 2013). Oxidative stress, hypoxia, Ang II, and certain peptides (e.g., human epidermal growth factor receptor-2 (HER-2), IL-1β, insulin) (Wolf, 2005; Curran and Keely, 2013) reduce HIF post-translational modifications that target the protein for degradation and thereby stabilize HIF expression.
The most well-described HIF-1α transcriptional responses involve the expression of genes whose products are involved in glycolysis and the production of lactate (Figure 3). Specifically, the HIF-1α: ARNT heterodimer promotes transcription of SLC2A1 (Solute Carrier Family two Member 1, GLUT1), HK1 (hexokinase 1), HK2 (hexokinase 2), PFK (phosphofructokinase), ALDOA (aldolase, fructose-bisphosphate A), GAPDH (glyceraldehyde-3-phosphate dehydrogenase), PGK1 (phosphoglycerate kinase 1), and LDHA (lactate dehydrogenase A) (Semenza et al., 1996; Jochmanova et al., 2013; Del Rey et al., 2017). Anaerobic metabolism decreases the levels of nicotinamide adenine dinucleotide (NAD) and increases the formation of the reduced form, NADH (Figure 3). Despite their differential functions in the RAAS, AT1R and AT2R can both induce HIF-1α stabilization in response to Ang II (Wolf, 2005; Liu et al., 2014). Understanding the roles of AT1R and AT2R HIF-1α cell signals in CKD requires further study.
The von Hippel-Lindau tumor suppressor (VHL) is an E3 Ubiquitin Ligase Which Ubiquitylates and targets the α-subunit of HIFs for oxygen-dependent proteolysis (Haase, 2009). Deletion of the VHL gene or increased production of HIF-2α in mouse podocytes leads to rapidly progressive glomerulonephritis that can be prevented by targeted deletion of the ARNT gene (Ding et al., 2013). Understanding whether AHR functions in the absence of ARNT in these cells may not only offer insight to the functions of podocytes, but also mechanisms in NAD metabolism, particularly since ARNT is a factor in both NAD salvage and de novo biosynthesis pathways.
The HIF-2α: ARNT heterodimer activates the transcription of nicotinamide phosphoribosyltransferase (NAMPT/visfatin) (Sun et al., 2020), the rate limiting enzyme in the NAD salvage pathway (Garten et al., 2015). Plasma levels of NAMPT are negatively correlated with glomerular filtration rate in nondiabetic hypertensive patients (Hsu et al., 2016), chronic glomerulonephritis patients, and diabetic nephropathy patients (Axelsson et al., 2007). As a cytokine, NAMPT promotes the production of inflammatory mediators, upregulates the expression of adhesion receptors and induces endothelial dysfunction (Romacho et al., 2013). Inside the cell, NAMPT catalyzes the production of nicotinamide mononucleotide (NMN) (Garten et al., 2015) (Figure 3). In HK-2 cells exposed to 1 mM hydrogen peroxide plus 1% oxygen, NMN increased cell viability and reduced collagen IV protein production. Similar results were obtained in a murine ischemia-reperfusion injury model, manifesting reduced tubular DNA damage, cellular injury, and fibrosis in response to intraperitoneal NMN therapy (Jia et al., 2021). These data suggest that neutralizing extracellular NAMPT or activating intracellular NAMPT production of NMN may be therapeutic strategies in treating CKD.
The AHR: ARNT heterodimer promotes the transcription of indoleamine 2,3- dioxygenase (IDO1) (Bessede et al., 2014), the rate limiting enzyme in the NAD de novo biosynthesis pathway. This pathway catabolizes tryptophan into NAD through a series of enzymatic reactions, which are also part of the kynurenine pathway (Ralto et al., 2020) (Figure 3). In a small study of CKD patients, plasma IDO1 activity level and its downstream metabolites (kynurenine, kynurenic-acid, quinolinic-acid) correlated with disease severity (Schefold et al., 2009). This finding concurs with conclusions from a subsequent study correlating serum IDO1 and kynurenine levels with disease severity (Bao et al., 2013). A meta-analysis indicates that the lower estimated glomerular filtration rate in these patients is associated with higher blood metabolite levels of tryptophan metabolites, including kynurenine, C-glycosyltryptophan (glycosylated amino acid), 3-indoxyl sulfate, and indole-3-lactate (Cheng et al., 2020). Each of these studies demonstrate an increase in the production of AHR ligands and a decrease in the production of NAD from the de novo biosynthesis pathway.
Quinolinate phosphoribosyltransferase (QPRT) is the final enzyme in the de novo biosynthesis pathway (Figure 3). In QPRT+/−mice, lower levels of NAD in the kidney and higher urinary levels of quinolinate are identified. In response to renal ischemia-reperfusion injury in wild-type mice, kidney QRPT expression levels are reduced and urinary quinolinate levels are elevated. These models were supplemented with intraperitoneal injections of 400 mg/kg nicotinamide, which ameliorated kidney function (Poyan Mehr et al., 2018), presumably through the production of NAD in the salvage pathway (Figure 3). In a small study of patients with COVID-19-related acute kidney injury, 1 g oral nicotinamide/day over 7 days, reduced mortality and renal replacement therapy, highlighting a potential therapeutic function in promoting NAD via the salvage pathway (Raines et al., 2021). Because a primary AHR-induced gene and regulator, TIPARP, also requires NAD for full activation (Zhang L. et al., 2020), further exploration of TIPARP in CKD progression may provide insight into the therapeutic functions of intracellular NAD.
The TGF-β1 Pathway and AHR
AHR is an integral regulator of extracellular matrix assembly and remodeling. AHR competition with HIF-1α for ARNT may be a mechanism which antagonizes three pro-fibrotic processes: hypoxia induction of TGF-β1, leading to suppressed collagen expression (Mingyuan et al., 2018); hypoxia-induced collagen prolyl hydroxylases (P4HA1 and P4HA2) required for collagen maturation and deposition (Gilkes et al., 2013); and hypoxia-induced enzymes (e.g., LOX, transglutaminases, lysyl hydroxylases) involved in collagen cross-linking (Curran and Keely, 2013; Gilkes et al., 2013). The mechanisms by which ligand activated AHR inhibits alpha-smooth muscle actin and collagen I expression and promotes MMP-1 expression are not fully known but may involve AHR crosstalk with various signaling pathways (Poormasjedi-Meibod et al., 2016; Shi et al., 2020).
Two key signaling pathways in renal fibrosis include the TGF-β1 pathway and the NF-κB pathway, which can also exhibit crosstalk between each other and with AHR. TGF-β1, β2 and β3 initiate cell signals through activation of TGF-β receptor (TβR)-I and TβRII heterodimers. TβRII phosphorylates TβRI, which recruits and phosphorylates signaling transducer molecules. These receptor-regulated SMADs (e.g., SMAD2, SMAD3) co-localize with the common partner SMAD (SMAD4) prior to localizing to the nucleus and binding to target genes (Chen et al., 2018). SMAD3 also strongly interacts with both AHR and ARNT and promotes dissociation between AHR and ARNT, inhibiting AHR signals (Nakano et al., 2020).
SMAD7 is an inhibitor SMAD that is activated by TGF-β signaling, providing negative-feedback. SMAD7 is recruited to TβRI and prevents receptor-regulated SMAD docking and phosphorylation. SMAD7 also recruits E3 ubiquitin ligases to degrade TβRI, SMAD2 and SMAD3, creating a regulatory feedback loop in TGF-β signaling (Chen et al., 2018).
The RAAS pathway is integrated with the TGF-β cell signal pathway. In an animal model involving Ang II-induced renal fibrosis, Smad7 knockout mice exhibit elevated TGF-β/Smad3 signaling, more severe renal injury and increased progressive fibrosis compared to the wild-type (Liu et al., 2013). However, in Smad3 knockout mice, Ang-II-induced renal fibrosis and NF-κB-driven renal inflammation was significantly lower compared to the wild-type (Liu et al., 2012b), highlighting functions of Ang II in promoting TGF-β cell signals.
Moreover, in mice with unilateral ureteral obstruction nephropathy, deletion of ACE2 results in a fourfold increase in the ratio of intrarenal Ang II/Ang 1-7, which was associated with increased tubulointerstitial fibrosis and inflammation (Liu et al., 2012a). Subsequent mechanistic studies in Ace2 knockout mice subjected to chronic subcutaneous angiotensin II infusion revealed an increase in Smad-specific E3 ubiquitin protein ligase 2 (SMURF2), a decrease in renal SMAD7, and increased TGF-β and NF-κB (Liu et al., 2017).
Because ACE2 is not known to directly transduce signals, a product of ACE2 activity, Ang (1–7), may function in the regulation of TGF-β cell signaling. Ang (1–7) binds the AT2R and the Mas receptor (Curran et al., 2020). The AT2R agonist, CGP42112A, promotes AT2R co-localization with TβRII for subsequent TβRII degradation (Guo et al., 2016). Possibly, Ang (1–7) activation of AT2R also induces the production of SMAD7. Because AHR induces ACE2 production (Lv et al., 2021) AHR may play a role in each of these responses (Figure 3).
The NF-KB Pathway and AHR
AHR interacts with both the canonical and non-canonical NF-κB pathways. The NF-κB transcription factor family consists of five proteins: p65 (RelA), RelB, c-Rel, p105/p50 (NF-κB1), and p100/p52 (NF-κB2). NF-κB1 and NF-κB2 are produced as inactive precursors, p105 and p100, respectively. RelB additionally associates with p100. Cell signals induce proteolytic processing of the inactive precursors, generating functional subunits p50 and p52. The Rel proteins, p65 and c-Rel, are similarly bound to inhibitory protein kinases (e.g., IκBα, IκBβ and IκBε). Cell signal-induced phosphorylation of inhibitory kinases targets the kinases for degradation and release p65 or c-Rel. The various NF-κB proteins form transcriptionally active homo- and heterodimeric complexes. The p65 transcription factor most commonly associates with p50 but can also form homodimers or associate with c-Rel and p52. RelB is only known to form heterodimers with either p50 or p52. The canonical pathway involves the activation of p65/p50 whereas the non-canonical pathway involves RelB (Hayden and Ghosh, 2004; Oeckinghaus and Ghosh, 2009). In mouse embryonic fibroblasts, p65 and RelB exhibit negative crosstalk (Marienfeld et al., 2003; Jacque et al., 2005) and in mouse kidney fibroblasts, RelB suppresses the production of TNF (Xia et al., 1999), which is a common mediator in CKD (Stenvinkel et al., 2021) (Figure 5).
FIGURE 5. Regulation of NF-κB in CKD. (1) Common NF-κB dimer pairs include p65/RelA and p50 in the canonical pathway and RelB and p52 in the non-canonical pathway. Non-canonical cell signals may antagonize canonical cell signals in fibroblasts. (2) AHR dimerizes with RelB in the production of IL-8. AHR or PPAR-γ activation promotes ubiquitination and degradation of p65/RelA. (3) Estrogen activates estrogen receptors (ER-α/β) to produce the NF-κB inhibitor, IκBα, and promotes the recruitment of ER-β to p65 binding sites, which blocks p65 transcriptional activity. (4) Heat shock protein (HSP)-90 is a chaperone shared by ER-α/β, PPAR-γ, AHR, and canonical NF-κB. (5) Elevated levels of p65/RelA, RelB, and HSP90 are found in CKD patient serum.
In the canonical NF-κB pathway, dioxin-activated AHR promotes p65 ubiquitination for degradation by either the proteasome or lysosome in mouse peritoneal macrophages, (Dominguez-Acosta et al., 2018). AHR also promotes the degradation of ER-α (Luecke-Johansson et al., 2017) and PPAR-γ (Dou et al., 2019), which are both involved in p65 inhibition. Specifically, PPAR-γ promotes p65 ubiquitination for targeted proteasome degradation (Hou et al., 2012) whereas estrogen induces the production of the NF-κB inhibitor, IκBα, and promotes the recruitment of ER-β to p65 binding sites, which blocks p65 transcriptional activity (Xing et al., 2012) (Figure 5). Because animal models of glomerulosclerosis treated with 17β-estradiol (Maric et al., 2004) or pioglitazone (Nemeth et al., 2019) exhibit reduced tubulointerstitial fibrosis, estrogen and PPAR-γ cell signals may regulate CKD pathogenesis by inhibiting canonical NF-κB signaling.
A common factor in ER-α/β (Powell et al., 2010), PPAR-γ (Nguyen et al., 2013) and AHR (Soshilov and Denison, 2011) cell signaling is heat shock protein (HSP)-90. This chaperone contributes to the stabilization of IκB kinase (IKK), which is needed for the dissociation of IκB from NF-κB (O’Neill et al., 2015). In chronic glomerulonephritis patients, serum levels of HSP90 and NF-κB are higher than those in healthy individuals. (Chebotareva et al., 2020). The HSP90 inhibitor, geldanamycin, significantly suppresses angiotensin II-induced p65 nuclear translocation in cardiac cells (Lee et al., 2010) and in a murine renal ischemia-reperfusion injury model, pre-treatment with the HSP90 inhibitor, AT13387, improved renal function compared to controls (O'Neill et al., 2015). Understanding the potential competition for HSP90 in the ER-α/β, PPAR-γ, NF-κB, and AHR pathways may help in identifying novel therapeutics for CKD (Figure 5).
In the non-canonical NF-κB pathway, dioxin-activated AHR can dimerize with RelB and promote IL-8 production in U937 macrophages. RelB:AHR complexes bind RelB:p52 response elements as well as AHR response elements (Vogel et al., 2007), highlighting the complexity of AHR in the non-canonical pathway. RelB is expressed in renal tubular epithelial cells and levels gradually increase with progressive fibrosis in a mouse renal fibrosis model with unilateral ureteral obstruction. RelB immunohistochemical staining in renal tubular epithelial cells was also positively correlated with the intensity of kidney fibrosis in biopsy specimens in a study of 34 CKD patients. Interestingly, the serum RelB levels from CKD patients also correlated with the intensity of renal fibrosis compared healthy controls (Sun D. et al., 2021). This dysregulated RelB response may also reflect changes in AHR cell signals that regulate fibrosis. Further investigation of RelB:AHR initiated cell signals, particularly in response to uremic AHR ligands, may offer insight into CKD pathogenesis.
Conclusion
AHR is a pleotropic cell signaling molecule with diverse ligand-specific functions. The elevated levels of uremic solutes that act as AHR ligands during the progression of CKD highlight the significance of AHR activity in these diseases. AHR contributes to the biotransformation of molecules in the clearance of xenobiotics, and these processes deserve further exploration in kidney pathophysiology. AHR competition with HIF-1α for binding to ARNT in pro-inflammatory and anaerobic responses, together with AHR antagonism of TGF-β1 cell signaling in fibrogenesis, support potential targeting of AHR to slow CKD progression. In the NAD de novo biosynthesis pathway, AHR stimulates RNA expression and protein production of the rate-limiting enzyme, IDO1, and binds molecules along this pathway that accumulate in CKD. NAD is required for the activity of TIPARP, which is involved in the recruitment of an E3 ligase for ubiquitin-mediated proteasome degradation of AHR. It is possible that the extracellular release of kynurenine and NAMPT, rather than intracellular metabolic catabolism of these molecules into NAD, alters the functions of AHR in CKD. Further investigation of AHR regulation of ACE2 and the downstream effects of the ACE2 cleavage product, Ang-(1–7), on Mas and AT2R may identify novel therapeutic targets in hypertension and fibrosis. Because each of these AHR functions may be regulated by crosstalk with ER-α, PPAR-γ, or NF-κB subunits, a more refined assessment of the binding affinity and availability of HSP90 in these cell signaling pathways during CKD is warranted.
Author Contributions
Wrote or contributed to the writing of the manuscript: CC and JK. Illustrations: CC. Developed tables: CC and JK.
Funding
This work was supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases Intramural Research Program and the National Institutes of Health Clinical Center.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Addi, T., Poitevin, S., McKay, N., El Mecherfi, K. E., Kheroua, O., Jourde-Chiche, N., et al. (2019). Mechanisms of Tissue Factor Induction by the Uremic Toxin Indole-3 Acetic Acid through Aryl Hydrocarbon Receptor/nuclear Factor-Kappa B Signaling Pathway in Human Endothelial Cells. Arch. Toxicol. 93 (1), 121–136. doi:10.1007/s00204-018-2328-3
Almaimani, M., Sridhar, V. S., and Cherney, D. Z. I. (2021). Sodium-glucose Cotransporter 2 Inhibition in Non-diabetic Kidney Disease. Curr. Opin. Nephrol. Hypertens. 30, 474–481. doi:10.1097/MNH.0000000000000724
Angelos, M. G., and Kaufman, D. S. (2018). Advances in the Role of the Aryl Hydrocarbon Receptor to Regulate Early Hematopoietic Development. Curr. Opin. Hematol. 25 (4), 273–278. doi:10.1097/MOH.0000000000000432
Asai, H., Hirata, J., and Watanabe-Akanuma, M. (2018). Indoxyl Glucuronide, a Protein-Bound Uremic Toxin, Inhibits Hypoxia-Inducible Factor‒dependent Erythropoietin Expression through Activation of Aryl Hydrocarbon Receptor. Biochem. Biophys. Res. Commun. 504 (2), 538–544. doi:10.1016/j.bbrc.2018.09.018
Assefa, E. G., Yan, Q., Gezahegn, S. B., Salissou, M. T. M., He, S., Wu, N., et al. (20192019). Role of Resveratrol on Indoxyl Sulfate-Induced Endothelial Hyperpermeability via Aryl Hydrocarbon Receptor (AHR)/Src-Dependent Pathway. Oxid Med. Cel Longev 2019, 5847040. doi:10.1155/2019/5847040
Auclair, M., Vigouroux, C., Boccara, F., Capel, E., Vigeral, C., Guerci, B., et al. (2013). Peroxisome Proliferator-Activated Receptor-γ Mutations Responsible for Lipodystrophy with Severe Hypertension Activate the Cellular Renin-Angiotensin System. Arterioscler Thromb. Vasc. Biol. 33 (4), 829–838. doi:10.1161/ATVBAHA.112.300962
Avilla, M. N., Malecki, K. M. C., Hahn, M. E., Wilson, R. H., and Bradfield, C. A. (2020). The Ah Receptor: Adaptive Metabolism, Ligand Diversity, and the Xenokine Model. Chem. Res. Toxicol. 33 (4), 860–879. doi:10.1021/acs.chemrestox.9b00476
Axelsson, J., Witasp, A., Carrero, J. J., Qureshi, A. R., Suliman, M. E., Heimbürger, O., et al. (2007). Circulating Levels of Visfatin/pre-B-Cell colony-enhancing Factor 1 in Relation to Genotype, GFR, Body Composition, and Survival in Patients with CKD. Am. J. Kidney Dis. 49 (2), 237–244. doi:10.1053/j.ajkd.2006.11.021
Balog, A., Varga, B., Fülöp, F., Lantos, I., Toldi, G., Vécsei, L., et al. (2021). Kynurenic Acid Analog Attenuates the Production of Tumor Necrosis Factor-α, Calgranulins (S100A 8/9 and S100A 12), and the Secretion of HNP1-3 and Stimulates the Production of Tumor Necrosis Factor-Stimulated Gene-6 in Whole Blood Cultures of Patients with Rheumatoid Arthritis. Front. Immunol. 12, 632513. doi:10.3389/fimmu.2021.632513
Bao, Y. S., Ji, Y., Zhao, S. L., Ma, L. L., Xie, R. J., and Na, S. P. (2013). Serum Levels and Activity of Indoleamine2,3-Dioxygenase and Tryptophanyl-tRNA Synthetase and Their Association with Disease Severity in Patients with Chronic Kidney Disease. Biomarkers 18 (5), 379–385. doi:10.3109/1354750X.2013.790074
Bass, S. E., Sienkiewicz, P., Macdonald, C. J., Cheng, R. Y., Sparatore, A., Del Soldato, P., et al. (2009). Novel Dithiolethione-Modified Nonsteroidal Anti-inflammatory Drugs in Human Hepatoma HepG2 and colon LS180 Cells. Clin. Cancer Res. 15 (6), 1964–1972. doi:10.1158/1078-0432.CCR-08-1870
Basso, M., Berlin, J., Xia, L., Sleiman, S. F., Ko, B., Haskew-Layton, R., et al. (2012). Transglutaminase Inhibition Protects against Oxidative Stress-Induced Neuronal Death Downstream of Pathological ERK Activation. J. Neurosci. 32 (19), 6561–6569. doi:10.1523/JNEUROSCI.3353-11.2012
Becker, J. L., Miller, F., Nuovo, G. J., Josepovitz, C., Schubach, W. H., and Nord, E. P. (1999). Epstein-Barr Virus Infection of Renal Proximal Tubule Cells: Possible Role in Chronic Interstitial Nephritis. J. Clin. Invest. 104 (12), 1673–1681. doi:10.1172/JCI7286
Bengtsson, A. A., Sturfelt, G., Lood, C., Rönnblom, L., van Vollenhoven, R. F., Axelsson, B., et al. (2012). Pharmacokinetics, Tolerability, and Preliminary Efficacy of Paquinimod (ABR-215757), a New Quinoline-3-Carboxamide Derivative: Studies in Lupus-Prone Mice and a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Dose-Ranging Study in Patients with Systemic Lupus Erythematosus. Arthritis Rheum. 64 (5), 1579–1588. doi:10.1002/art.33493
Bessede, A., Gargaro, M., Pallotta, M. T., Matino, D., Servillo, G., Brunacci, C., et al. (2014). Aryl Hydrocarbon Receptor Control of a Disease Tolerance Defence Pathway. Nature 511 (7508), 184–190. doi:10.1038/nature13323
Bhogal, R. K., Stoica, C. M., McGaha, T. L., and Bona, C. A. (2005). Molecular Aspects of Regulation of Collagen Gene Expression in Fibrosis. J. Clin. Immunol. 25 (6), 592–603. doi:10.1007/s10875-005-7827-3
Bock, K. W., and Bock-Hennig, B. S. (2010). UDP-glucuronosyltransferases (UGTs): from Purification of Ah-Receptor-Inducible UGT1A6 to Coordinate Regulation of Subsets of CYPs, UGTs, and ABC Transporters by Nuclear Receptors. Drug Metab. Rev. 42 (1), 6–13. doi:10.3109/03602530903205492
Bolati, D., Shimizu, H., Higashiyama, Y., Nishijima, F., and Niwa, T. (2011). Indoxyl Sulfate Induces Epithelial-To-Mesenchymal Transition in Rat Kidneys and Human Proximal Tubular Cells. Am. J. Nephrol. 34 (4), 318–323. doi:10.1159/000330852
Boros, F., and Vécsei, L. (2020). Progress in the Development of Kynurenine and Quinoline-3-Carboxamide-Derived Drugs. Expert Opin. Investig. Drugs 29 (11), 1223–1247. doi:10.1080/13543784.2020.1813716
Brinkmann, V., Ale-Agha, N., Haendeler, J., and Ventura, N. (2019). The Aryl Hydrocarbon Receptor (AhR) in the Aging Process: Another Puzzling Role for This Highly Conserved Transcription Factor. Front. Physiol. 10, 1561. doi:10.3389/fphys.2019.01561
Buetow, L., and Huang, D. T. (2016). Structural Insights into the Catalysis and Regulation of E3 Ubiquitin Ligases. Nat. Rev. Mol. Cel Biol 17 (10), 626–642. doi:10.1038/nrm.2016.91
Bülow, R. D., and Boor, P. (2019). Extracellular Matrix in Kidney Fibrosis: More Than Just a Scaffold. J. Histochem. Cytochem. 67 (9), 643–661. doi:10.1369/0022155419849388
Chaudhary, N. I., Roth, G. J., Hilberg, F., Müller-Quernheim, J., Prasse, A., Zissel, G., et al. (2007). Inhibition of PDGF, VEGF and FGF Signalling Attenuates Fibrosis. Eur. Respir. J. 29 (5), 976–985. doi:10.1183/09031936.00152106
Chebotareva, N., Vinogradov, A., Gindis, A., Tao, E., and Moiseev, S. (2020). Heat Shock Protein 90 and NFkB Levels in Serum and Urine in Patients with Chronic Glomerulonephritis. Cell Stress Chaperones 25 (3), 495–501. doi:10.1007/s12192-020-01089-x
Chen, L., Yang, T., Lu, D. W., Zhao, H., Feng, Y. L., Chen, H., et al. (2018). Central Role of Dysregulation of TGF-β/Smad in CKD Progression and Potential Targets of its Treatment. Biomed. Pharmacother. 101, 670–681. doi:10.1016/j.biopha.2018.02.090
Cheng, Y., Li, Y., Benkowitz, P., Lamina, C., Köttgen, A., and Sekula, P. (2020). The Relationship between Blood Metabolites of the Tryptophan Pathway and Kidney Function: a Bidirectional Mendelian Randomization Analysis. Sci. Rep. 10 (1), 12675. doi:10.1038/s41598-020-69559-x
Cho, M. E., Smith, D. C., Branton, M. H., Penzak, S. R., and Kopp, J. B. (2007). Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2 (5), 906–913. doi:10.2215/CJN.01050207
Ciolino, H. P., MacDonald, C. J., Memon, O. S., Bass, S. E., and Yeh, G. C. (2006). Sulindac Regulates the Aryl Hydrocarbon Receptor-Mediated Expression of Phase 1 Metabolic Enzymes In Vivo and In Vitro. Carcinogenesis 27 (8), 1586–1592. doi:10.1093/carcin/bgi359
Cui, Y., Zhang, M., Leng, C., Blokzijl, T., Jansen, B. H., Dijkstra, G., et al. (2020). Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts. Cells 9 (3). doi:10.3390/cells9030775
Curran, C. S., Bolig, T., and Torabi-Parizi, P. (2018). Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection. Am. J. Respir. Crit. Care Med. 197 (6), 708–727. doi:10.1164/rccm.201705-1043SO
Curran, C. S., Gupta, S., Sanz, I., and Sharon, E. (2019). PD-1 Immunobiology in Systemic Lupus Erythematosus. J. Autoimmun. 97, 1–9. doi:10.1016/j.jaut.2018.10.025
Curran, C. S., and Keely, P. J. (2013). Breast Tumor and Stromal Cell Responses to TGF-β and Hypoxia in Matrix Deposition. Matrix Biol. 32 (2), 95–105. doi:10.1016/j.matbio.2012.11.016
Curran, C. S., and Kopp, J. B. (2021). PD-1 Immunobiology in Glomerulonephritis and Renal Cell Carcinoma. BMC Nephrol. 22 (1), 80. doi:10.1186/s12882-021-02257-6
Curran, C. S., Rivera, D. R., and Kopp, J. B. (2020). COVID-19 Usurps Host Regulatory Networks. Front. Pharmacol. 11, 1278. doi:10.3389/fphar.2020.01278
Daher, Ede. F., da Silva, G. B., and Barros, E. J. (2013). Renal Tuberculosis in the Modern Era. Am. J. Trop. Med. Hyg. 88 (1), 54–64. doi:10.4269/ajtmh.2013.12-0413
Del Rey, M. J., Valín, Á., Usategui, A., García-Herrero, C. M., Sánchez-Aragó, M., Cuezva, J. M., et al. (2017). Hif-1α Knockdown Reduces Glycolytic Metabolism and Induces Cell Death of Human Synovial Fibroblasts under Normoxic Conditions. Sci. Rep. 7 (1), 3644. doi:10.1038/s41598-017-03921-4
Deng, C., Dang, F., Gao, J., Zhao, H., Qi, S., and Gao, M. (2018). Acute Benzo[a]pyrene Treatment Causes Different Antioxidant Response and DNA Damage in Liver, Lung, Brain, Stomach and Kidney. Heliyon 4 (11), e00898. doi:10.1016/j.heliyon.2018.e00898
Ding, M., Coward, R. J., Jeansson, M., Kim, W., and Quaggin, S. E. (2013). Regulation of Hypoxia-Inducible Factor 2-a Is Essential for Integrity of the Glomerular Barrier. Am. J. Physiol. Ren. Physiol 304 (1), F120–F126. doi:10.1152/ajprenal.00416.2012
Domínguez-Acosta, O., Vega, L., Estrada-Muñiz, E., Rodríguez, M. S., Gonzalez, F. J., and Elizondo, G. (2018). Activation of Aryl Hydrocarbon Receptor Regulates the LPS/IFNγ-induced Inflammatory Response by Inducing Ubiquitin-Proteosomal and Lysosomal Degradation of RelA/p65. Biochem. Pharmacol. 155, 141–149. doi:10.1016/j.bcp.2018.06.016
Dou, H., Duan, Y., Zhang, X., Yu, Q., Di, Q., Song, Y., et al. (2019). Aryl Hydrocarbon Receptor (AhR) Regulates Adipocyte Differentiation by Assembling CRL4B Ubiquitin Ligase to Target PPARγ for Proteasomal Degradation. J. Biol. Chem. 294 (48), 18504–18515. doi:10.1074/jbc.RA119.009282
Dou, L., Sallée, M., Cerini, C., Poitevin, S., Gondouin, B., Jourde-Chiche, N., et al. (2015). The Cardiovascular Effect of the Uremic Solute Indole-3 Acetic Acid. J. Am. Soc. Nephrol. 26 (4), 876–887. doi:10.1681/ASN.2013121283
Effner, R., Hiller, J., Eyerich, S., Traidl-Hoffmann, C., Brockow, K., Triggiani, M., et al. (2017). Cytochrome P450s in Human Immune Cells Regulate IL-22 and C-Kit via an AHR Feedback Loop. Sci. Rep. 7, 44005. doi:10.1038/srep44005
El-Naga, R. N., and Mahran, Y. F. (2016). Indole-3-carbinol Protects against Cisplatin-Induced Acute Nephrotoxicity: Role of Calcitonin Gene-Related Peptide and Insulin-like Growth Factor-1. Sci. Rep. 6, 29857. doi:10.1038/srep29857
Evani, S. J., Karna, S. L. R., Seshu, J., and Leung, K. P. (2020). Pirfenidone Regulates LPS Mediated Activation of Neutrophils. Sci. Rep. 10 (1), 19936. doi:10.1038/s41598-020-76271-3
Falahatpisheh, M. H., and Ramos, K. S. (2003). Ligand-activated Ahr Signaling Leads to Disruption of Nephrogenesis and Altered Wilms' Tumor Suppressor mRNA Splicing. Oncogene 22 (14), 2160–2171. doi:10.1038/sj.onc.1206238
Falconi, C. A., Junho, C. V. D. C., Fogaça-Ruiz, F., Vernier, I. C. S., da Cunha, R. S., Stinghen, A. E. M., et al. (2021). Uremic Toxins: An Alarming Danger Concerning the Cardiovascular System. Front. Physiol. 12, 686249. doi:10.3389/fphys.2021.686249
Faqah, A., and Jafar, T. H. (2011). Control of Blood Pressure in Chronic Kidney Disease: How Low to Go? Nephron Clin. Pract. 119 (4), c324–2. doi:10.1159/000331066
Finnigan, N. A., and Leslie, S. W. (2021). “Polycystic Kidney Disease in Adults,” in StatPearls. (Treasure Island (FL)).
Fontecha-Barriuso, M., Martín-Sanchez, D., Martinez-Moreno, J. M., Cardenas-Villacres, D., Carrasco, S., Sanchez-Niño, M. D., et al. (2020). Molecular Pathways Driving Omeprazole Nephrotoxicity. Redox Biol. 32, 101464. doi:10.1016/j.redox.2020.101464
Fransén Pettersson, N., Deronic, A., Nilsson, J., Hannibal, T. D., Hansen, L., Schmidt-Christensen, A., et al. (2018). The Immunomodulatory Quinoline-3-Carboxamide Paquinimod Reverses Established Fibrosis in a Novel Mouse Model for Liver Fibrosis. PLoS One 13 (9), e0203228. doi:10.1371/journal.pone.0203228
Frauenstein, K., Tigges, J., Soshilov, A. A., Kado, S., Raab, N., Fritsche, E., et al. (2015). Activation of the Aryl Hydrocarbon Receptor by the Widely Used Src Family Kinase Inhibitor 4-Amino-5-(4-Chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-D]pyrimidine (PP2). Arch. Toxicol. 89 (8), 1329–1336. doi:10.1007/s00204-014-1321-8
Fu, Q., Colgan, S. P., and Shelley, C. S. (2016). Hypoxia: The Force that Drives Chronic Kidney Disease. Clin. Med. Res. 14 (1), 15–39. doi:10.3121/cmr.2015.1282
Garten, A., Schuster, S., Penke, M., Gorski, T., de Giorgis, T., and Kiess, W. (2015). Physiological and Pathophysiological Roles of NAMPT and NAD Metabolism. Nat. Rev. Endocrinol. 11 (9), 535–546. doi:10.1038/nrendo.2015.117
Ghoshal, S., and Freedman, B. I. (2019). Mechanisms of Stroke in Patients with Chronic Kidney Disease. Am. J. Nephrol. 50 (4), 229–239. doi:10.1159/000502446
Gilkes, D. M., Bajpai, S., Chaturvedi, P., Wirtz, D., and Semenza, G. L. (2013). Hypoxia-inducible Factor 1 (HIF-1) Promotes Extracellular Matrix Remodeling under Hypoxic Conditions by Inducing P4HA1, P4HA2, and PLOD2 Expression in Fibroblasts. J. Biol. Chem. 288 (15), 10819–10829. doi:10.1074/jbc.M112.442939
Goda, N., and Kanai, M. (2012). Hypoxia-inducible Factors and Their Roles in Energy Metabolism. Int. J. Hematol. 95 (5), 457–463. doi:10.1007/s12185-012-1069-y
Guo, B., Koya, D., Isono, M., Sugimoto, T., Kashiwagi, A., and Haneda, M. (2004). Peroxisome Proliferator-Activated Receptor-Gamma Ligands Inhibit TGF-Beta 1-induced Fibronectin Expression in Glomerular Mesangial Cells. Diabetes 53 (1), 200–208. doi:10.2337/diabetes.53.1.200
Guo, H. L., Liao, X. H., Liu, Q., and Zhang, L. (2016). Angiotensin II Type 2 Receptor Decreases Transforming Growth Factor-β Type II Receptor Expression and Function in Human Renal Proximal Tubule Cells. PLoS One 11 (2), e0148696. doi:10.1371/journal.pone.0148696
Haase, V. H. (2009). The VHL Tumor Suppressor: Master Regulator of HIF. Curr. Pharm. Des. 15 (33), 3895–3903. doi:10.2174/138161209789649394
Haendel, M., Vasilevsky, N., Unni, D., Bologa, C., Harris, N., Rehm, H., et al. (2020). How many Rare Diseases Are There? Nat. Rev. Drug Discov. 19 (2), 77–78. doi:10.1038/d41573-019-00180-y
Hamidi, S. H., Kadamboor Veethil, S., and Hamidi, S. H. (2021). Role of Pirfenidone in TGF-β Pathways and Other Inflammatory Pathways in Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) Infection: a Theoretical Perspective. Pharmacol. Rep. 73 (3), 712–727. doi:10.1007/s43440-021-00255-x
Hayden, M. S., and Ghosh, S. (2004). Signaling to NF-kappaB. Genes Dev. 18 (18), 2195–2224. doi:10.1101/gad.1228704
Heck, T., Faccio, G., Richter, M., and Thöny-Meyer, L. (2013). Enzyme-catalyzed Protein Crosslinking. Appl. Microbiol. Biotechnol. 97 (2), 461–475. doi:10.1007/s00253-012-4569-z
Hellms, S., Gueler, F., Gutberlet, M., Schebb, N. H., Rund, K., Kielstein, J. T., et al. (2019). Single-dose Diclofenac in Healthy Volunteers Can Cause Decrease in Renal Perfusion Measured by Functional Magnetic Resonance Imaging. J. Pharm. Pharmacol. 71 (8), 1262–1270. doi:10.1111/jphp.13105
Hou, Y., Moreau, F., and Chadee, K. (2012). PPARγ Is an E3 Ligase that Induces the Degradation of NFκB/p65. Nat. Commun. 3, 1300. doi:10.1038/ncomms2270
Hsu, C. Y., Huang, P. H., Chen, T. H., Chiang, C. H., Leu, H. B., Huang, C. C., et al. (2016). Increased Circulating Visfatin Is Associated with Progression of Kidney Disease in Non-diabetic Hypertensive Patients. Am. J. Hypertens. 29 (4), 528–536. doi:10.1093/ajh/hpv132
Hubbi, M. E., Hu, H., KshitizAhmed, I., Ahmed, I., Levchenko, A., and Semenza, G. L. (2013). Chaperone-mediated Autophagy Targets Hypoxia-Inducible Factor-1α (HIF-1α) for Lysosomal Degradation. J. Biol. Chem. 288 (15), 10703–10714. doi:10.1074/jbc.M112.414771
Ichihara, S., Li, P., Mise, N., Suzuki, Y., Izuoka, K., Nakajima, T., et al. (2019). Ablation of Aryl Hydrocarbon Receptor Promotes Angiotensin II-Induced Cardiac Fibrosis through Enhanced C-Jun/HIF-1α Signaling. Arch. Toxicol. 93 (6), 1543–1553. doi:10.1007/s00204-019-02446-1
Ichii, O., Otsuka-Kanazawa, S., Nakamura, T., Ueno, M., Kon, Y., Chen, W., et al. (2014). Podocyte Injury Caused by Indoxyl Sulfate, a Uremic Toxin and Aryl-Hydrocarbon Receptor Ligand. PLoS One 9 (9), e108448. doi:10.1371/journal.pone.0108448
Ito, I., Hanyu, A., Wayama, M., Goto, N., Katsuno, Y., Kawasaki, S., et al. (2010). Estrogen Inhibits Transforming Growth Factor Beta Signaling by Promoting Smad2/3 Degradation. J. Biol. Chem. 285 (19), 14747–14755. doi:10.1074/jbc.M109.093039
Ito, S., Osaka, M., Edamatsu, T., Itoh, Y., and Yoshida, M. (2016). Crucial Role of the Aryl Hydrocarbon Receptor (AhR) in Indoxyl Sulfate-Induced Vascular Inflammation. J. Atheroscler. Thromb. 23 (8), 960–975. doi:10.5551/jat.34462
Itoh, Y., Ezawa, A., Kikuchi, K., Tsuruta, Y., and Niwa, T. (2013). Correlation between Serum Levels of Protein-Bound Uremic Toxins in Hemodialysis Patients Measured by LC/MS/MS. Mass. Spectrom. (Tokyo) 2, S0017. doi:10.5702/massspectrometry.S0017
Jacque, E., Tchenio, T., Piton, G., Romeo, P. H., and Baud, V. (2005). RelA Repression of RelB Activity Induces Selective Gene Activation Downstream of TNF Receptors. Proc. Natl. Acad. Sci. U S A. 102 (41), 14635–14640. doi:10.1073/pnas.0507342102
Jankowski, J., Floege, J., Fliser, D., Böhm, M., and Marx, N. (2021). Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation 143 (11), 1157–1172. doi:10.1161/CIRCULATIONAHA.120.050686
Jennens, R. R., Rosenthal, M. A., Lindeman, G. J., and Michael, M. (2004). Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. Urol. Oncol. 22 (3), 193–196. doi:10.1016/j.urolonc.2004.01.011
Jia, Y., Kang, X., Tan, L., Ren, Y., Qu, L., Tang, J., et al. (2021). Nicotinamide Mononucleotide Attenuates Renal Interstitial Fibrosis after AKI by Suppressing Tubular DNA Damage and Senescence. Front. Physiol. 12, 649547. doi:10.3389/fphys.2021.649547
Jiang, J., Kang, T. B., Shim, do. W., Oh, N. H., Kim, T. J., and Lee, K. H. (2013). Indole-3-carbinol Inhibits LPS-Induced Inflammatory Response by Blocking TRIF-dependent Signaling Pathway in Macrophages. Food Chem. Toxicol. 57, 256–261. doi:10.1016/j.fct.2013.03.040
Jochmanová, I., Yang, C., Zhuang, Z., and Pacak, K. (2013). Hypoxia-inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction. J. Natl. Cancer Inst. 105 (17), 1270–1283. doi:10.1093/jnci/djt201
Johnson, T. S., Fisher, M., Haylor, J. L., Hau, Z., Skill, N. J., Jones, R., et al. (2007). Transglutaminase Inhibition Reduces Fibrosis and Preserves Function in Experimental Chronic Kidney Disease. J. Am. Soc. Nephrol. 18 (12), 3078–3088. doi:10.1681/ASN.2006070690
Kagami, S., Border, W. A., Miller, D. E., and Noble, N. A. (1994). Angiotensin II Stimulates Extracellular Matrix Protein Synthesis through Induction of Transforming Growth Factor-Beta Expression in Rat Glomerular Mesangial Cells. J. Clin. Invest. 93 (6), 2431–2437. doi:10.1172/JCI117251
Kashuba, E. V., Gradin, K., Isaguliants, M., Szekely, L., Poellinger, L., Klein, G., et al. (2006). Regulation of Transactivation Function of the Aryl Hydrocarbon Receptor by the Epstein-Barr Virus-Encoded EBNA-3 Protein. J. Biol. Chem. 281 (2), 1215–1223. doi:10.1074/jbc.M509036200
Kazancioğlu, R. (20132011). Risk Factors for Chronic Kidney Disease: an Update. Kidney Int. Supplements 3 (4), 368–371. doi:10.1038/kisup.2013.79
Kim, J. T., Kim, S. S., Jun, D. W., Hwang, Y. H., Park, W. H., Pak, Y. K., et al. (2013). Serum Arylhydrocarbon Receptor Transactivating Activity Is Elevated in Type 2 Diabetic Patients with Diabetic Nephropathy. J. Diabetes Investig. 4 (5), 483–491. doi:10.1111/jdi.12081
Knights, K. M., Rowland, A., and Miners, J. O. (2013). Renal Drug Metabolism in Humans: the Potential for Drug-Endobiotic Interactions Involving Cytochrome P450 (CYP) and UDP-Glucuronosyltransferase (UGT). Br. J. Clin. Pharmacol. 76 (4), 587–602. doi:10.1111/bcp.12086
Lamas Ferreiro, J. L., Álvarez Otero, J., González González, L., Novoa Lamazares, L., Arca Blanco, A., Bermúdez Sanjurjo, J. R., et al. (2017). Pseudomonas aeruginosa Urinary Tract Infections in Hospitalized Patients: Mortality and Prognostic Factors. PLoS One 12 (5), e0178178. doi:10.1371/journal.pone.0178178
Lee, K. H., Jang, Y., and Chung, J. H. (2010). Heat Shock Protein 90 Regulates IκB Kinase Complex and NF-Κb Activation in Angiotensin II-Induced Cardiac Cell Hypertrophy. Exp. Mol. Med. 42 (10), 703–711. doi:10.3858/emm.2010.42.10.069
Lees, M. J., Peet, D. J., and Whitelaw, M. L. (2003). Defining the Role for XAP2 in Stabilization of the Dioxin Receptor. J. Biol. Chem. 278 (38), 35878–35888. doi:10.1074/jbc.M302430200
Li, J. H., Huang, X. R., Zhu, H. J., Oldfield, M., Cooper, M., Truong, L. D., et al. (2004). Advanced Glycation End Products Activate Smad Signaling via TGF-beta-dependent and Independent Mechanisms: Implications for Diabetic Renal and Vascular Disease. FASEB J. 18 (1), 176–178. doi:10.1096/fj.02-1117fje
Li, Y., Kilani, R. T., Rahmani-Neishaboor, E., Jalili, R. B., and Ghahary, A. (2014). Kynurenine Increases Matrix Metalloproteinase-1 and -3 Expression in Cultured Dermal Fibroblasts and Improves Scarring In Vivo. J. Invest. Dermatol. 134 (3), 643–650. doi:10.1038/jid.2013.303
Liabeuf, S., Laville, S. M., Glorieux, G., Cheddani, L., Brazier, F., Titeca Beauport, D., et al. (2020). Difference in Profiles of the Gut-Derived Tryptophan Metabolite Indole Acetic Acid between Transplanted and Non-transplanted Patients with Chronic Kidney Disease. Int. J. Mol. Sci. 21 (6). doi:10.3390/ijms21062031
Lin, Y. T., Wu, P. H., Lee, H. H., Mubanga, M., Chen, C. S., Kuo, M. C., et al. (2019). Indole-3 Acetic Acid Increased Risk of Impaired Cognitive Function in Patients Receiving Hemodialysis. Neurotoxicology 73, 85–91. doi:10.1016/j.neuro.2019.02.019
Liu, C., Zhang, J. W., Hu, L., Song, Y. C., Zhou, L., Fan, Y., et al. (2014). Activation of the AT1R/HIF-1 α/ACE axis Mediates Angiotensin II-Induced VEGF Synthesis in Mesenchymal Stem Cells. Biomed. Res. Int. 2014, 627380. doi:10.1155/2014/627380
Liu, G. X., Li, Y. Q., Huang, X. R., Wei, L., Chen, H. Y., Shi, Y. J., et al. (2013). Disruption of Smad7 Promotes ANG II-Mediated Renal Inflammation and Fibrosis via Sp1-TGF-β/Smad3-NF.κB-dependent Mechanisms in Mice. PLoS One 8 (1), e53573. doi:10.1371/journal.pone.0053573
Liu, Z., Huang, X. R., Chen, H. Y., Fung, E., Liu, J., and Lan, H. Y. (2017). Deletion of Angiotensin-Converting Enzyme-2 Promotes Hypertensive Nephropathy by Targeting Smad7 for Ubiquitin Degradation. Hypertension 70 (4), 822–830. doi:10.1161/HYPERTENSIONAHA.117.09600
Liu, Z., Huang, X. R., Chen, H. Y., Penninger, J. M., and Lan, H. Y. (2012a). Loss of Angiotensin-Converting Enzyme 2 Enhances TGF-β/Smad-Mediated Renal Fibrosis and NF-Κb-Driven Renal Inflammation in a Mouse Model of Obstructive Nephropathy. Lab. Invest. 92 (5), 650–661. doi:10.1038/labinvest.2012.2
Liu, Z., Huang, X. R., and Lan, H. Y. (2012b). Smad3 Mediates ANG II-Induced Hypertensive Kidney Disease in Mice. Am. J. Physiol. Ren. Physiol 302 (8), F986–F997. doi:10.1152/ajprenal.00595.2011
Lourenço, E. V., Wong, M., Hahn, B. H., Palma-Diaz, M. F., and Skaggs, B. J. (2014). Laquinimod Delays and Suppresses Nephritis in Lupus-Prone Mice and Affects Both Myeloid and Lymphoid Immune Cells. Arthritis Rheumatol. 66 (3), 674–685. doi:10.1002/art.38259
Lowenstein, J., and Nigam, S. K. (2021). Uremic Toxins in Organ Crosstalk. Front. Med. 8, 592602. doi:10.3389/fmed.2021.592602
Lu, H., Lei, X., and Klaassen, C. (2006). Gender Differences in Renal Nuclear Receptors and Aryl Hydrocarbon Receptor in 5/6 Nephrectomized Rats. Kidney Int. 70 (11), 1920–1928. doi:10.1038/sj.ki.5001880
Luecke-Johansson, S., Gralla, M., Rundqvist, H., Ho, J. C., Johnson, R. S., Gradin, K., et al. (2017). A Molecular Mechanism to Switch the Aryl Hydrocarbon Receptor from a Transcription Factor to an E3 Ubiquitin Ligase. Mol. Cel Biol 37 (13). doi:10.1128/MCB.00630-16
Lund, A. K., Goens, M. B., Kanagy, N. L., and Walker, M. K. (2003). Cardiac Hypertrophy in Aryl Hydrocarbon Receptor Null Mice Is Correlated with Elevated Angiotensin II, Endothelin-1, and Mean Arterial Blood Pressure. Toxicol. Appl. Pharmacol. 193 (2), 177–187. doi:10.1016/j.taap.2003.08.008
Lv, J., Yu, P., Wang, Z., Deng, W., Bao, L., Liu, J., et al. (2021). ACE2 Expression Is Regulated by AhR in SARS-CoV-2-Infected Macaques. Cell Mol Immunol 18 (5), 1308–1310. doi:10.1038/s41423-021-00672-1
Ma, Q., and Baldwin, K. T. (2000). 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced Degradation of Aryl Hydrocarbon Receptor (AhR) by the Ubiquitin-Proteasome Pathway. Role of the Transcription Activaton and DNA Binding of AhR. J. Biol. Chem. 275 (12), 8432–8438. doi:10.1074/jbc.275.12.8432
MacPherson, L., Tamblyn, L., Rajendra, S., Bralha, F., McPherson, J. P., and Matthews, J. (2013). 2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-Ribose) Polymerase (TiPARP, ARTD14) Is a Mono-ADP-Ribosyltransferase and Repressor of Aryl Hydrocarbon Receptor Transactivation. Nucleic Acids Res. 41 (3), 1604–1621. doi:10.1093/nar/gks1337
Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., et al. (2020). Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: a Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial. Lancet Respir. Med. 8 (2), 147–157. doi:10.1016/S2213-2600(19)30341-8
Mahringer, A., Bernd, A., Miller, D. S., and Fricker, G. (2019). Aryl Hydrocarbon Receptor Ligands Increase ABC Transporter Activity and Protein Expression in Killifish (Fundulus heteroclitus) Renal Proximal Tubules. Biol. Chem. 400 (10), 1335–1345. doi:10.1515/hsz-2018-0425
Maric, C., Sandberg, K., and Hinojosa-Laborde, C. (2004). Glomerulosclerosis and Tubulointerstitial Fibrosis Are Attenuated with 17beta-Estradiol in the Aging Dahl Salt Sensitive Rat. J. Am. Soc. Nephrol. 15 (6), 1546–1556. doi:10.1097/01.asn.0000128219.65330.ea
Marienfeld, R., May, M. J., Berberich, I., Serfling, E., Ghosh, S., and Neumann, M. (2003). RelB Forms Transcriptionally Inactive Complexes with RelA/p65. J. Biol. Chem. 278 (22), 19852–19860. doi:10.1074/jbc.M301945200
Martínez-Revelles, S., García-Redondo, A. B., Avendaño, M. S., Varona, S., Palao, T., Orriols, M., et al. (2017). Lysyl Oxidase Induces Vascular Oxidative Stress and Contributes to Arterial Stiffness and Abnormal Elastin Structure in Hypertension: Role of p38MAPK. Antioxid. Redox Signal. 27 (7), 379–397. doi:10.1089/ars.2016.6642
McIntosh, B. E., Hogenesch, J. B., and Bradfield, C. A. (2010). Mammalian Per-Arnt-Sim Proteins in Environmental Adaptation. Annu. Rev. Physiol. 72, 625–645. doi:10.1146/annurev-physiol-021909-135922
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., and Bradfield, C. A. (2010). An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells. J. Immunol. 185 (6), 3190–3198. doi:10.4049/jimmunol.0903670
Mezrich, J. D., Nguyen, L. P., Kennedy, G., Nukaya, M., Fechner, J. H., Zhang, X., et al. (2012). SU5416, a VEGF Receptor Inhibitor and Ligand of the AHR, Represents a New Alternative for Immunomodulation. PLoS One 7 (9), e44547. doi:10.1371/journal.pone.0044547
Mingyuan, X., Qianqian, P., Shengquan, X., Chenyi, Y., Rui, L., Yichen, S., et al. (2018). Hypoxia-inducible Factor-1α Activates Transforming Growth Factor-β1/Smad Signaling and Increases Collagen Deposition in Dermal Fibroblasts. Oncotarget 9 (3), 3188–3197. doi:10.18632/oncotarget.23225
Moiseev, S., Cohen Tervaert, J. W., Arimura, Y., Bogdanos, D. P., Csernok, E., Damoiseaux, J., et al. (2020). 2020 International Consensus on ANCA Testing beyond Systemic Vasculitis. Autoimmun. Rev. 19 (9), 102618. doi:10.1016/j.autrev.2020.102618
Morales, J. L., and Perdew, G. H. (2007). Carboxyl Terminus of Hsc70-Interacting Protein (CHIP) Can Remodel Mature Aryl Hydrocarbon Receptor (AhR) Complexes and Mediate Ubiquitination of Both the AhR and the 90 kDa Heat-Shock Protein (Hsp90) In Vitro. Biochemistry 46 (2), 610–621. doi:10.1021/bi062165b
Moura-Alves, P., Faé, K., Houthuys, E., Dorhoi, A., Kreuchwig, A., Furkert, J., et al. (2014). AhR Sensing of Bacterial Pigments Regulates Antibacterial Defence. Nature 512 (7515), 387–392. doi:10.1038/nature13684
Murray, M. D., Black, P. K., Kuzmik, D. D., Haag, K. M., Manatunga, A. K., Mullin, M. A., et al. (1995). Acute and Chronic Effects of Nonsteroidal Antiinflammatory Drugs on Glomerular Filtration Rate in Elderly Patients. Am. J. Med. Sci. 310 (5), 188–197. doi:10.1097/00000441-199511000-00003
Muthukumar, T., Jayakumar, M., Fernando, E. M., and Muthusethupathi, M. A. (2002). Acute Renal Failure Due to Rifampicin: a Study of 25 Patients. Am. J. Kidney Dis. 40 (4), 690–696. doi:10.1053/ajkd.2002.35675
Nakano, N., Sakata, N., Katsu, Y., Nochise, D., Sato, E., Takahashi, Y., et al. (2020). Dissociation of the AhR/ARNT Complex by TGF-β/Smad Signaling Represses CYP1A1 Gene Expression and Inhibits Benze[a]pyrene-Mediated Cytotoxicity. J. Biol. Chem. 295 (27), 9033–9051. doi:10.1074/jbc.RA120.013596
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., et al. (2021). Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Ann. Intern. Med. 174 (3), 385–394. doi:10.7326/M20-5938
Németh, Á., Mózes, M. M., Calvier, L., Hansmann, G., and Kökény, G. (2019). The PPARγ Agonist Pioglitazone Prevents TGF-β Induced Renal Fibrosis by Repressing EGR-1 and STAT3. BMC Nephrol. 20 (1), 245. doi:10.1186/s12882-019-1431-x
Ng, H. Y., Yisireyili, M., Saito, S., Lee, C. T., Adelibieke, Y., Nishijima, F., et al. (2014). Indoxyl Sulfate Downregulates Expression of Mas Receptor via OAT3/AhR/Stat3 Pathway in Proximal Tubular Cells. PLoS One 9 (3), e91517. doi:10.1371/journal.pone.0091517
Nguyen, L. T., Saad, S., Shi, Y., Wang, R., Chou, A. S. Y., Gill, A., et al. (2021). Lysyl Oxidase Inhibitors Attenuate Cyclosporin A-Induced Nephropathy in Mouse. Sci. Rep. 11 (1), 12437. doi:10.1038/s41598-021-91772-5
Nguyen, M. T., Csermely, P., and Sőti, C. (2013). Hsp90 Chaperones PPARγ and Regulates Differentiation and Survival of 3T3-L1 Adipocytes. Cell Death Differ 20 (12), 1654–1663. doi:10.1038/cdd.2013.129
Nihei, T., Miura, Y., and Yagasaki, K. (2001). Inhibitory Effect of Resveratrol on Proteinuria, Hypoalbuminemia and Hyperlipidemia in Nephritic Rats. Life Sci. 68 (25), 2845–2852. doi:10.1016/s0024-3205(01)01061-x
Nordio, M., Limido, A., Maggiore, U., Nichelatti, M., Postorino, M., Quintaliani, G., et al. (2012). Survival in Patients Treated by Long-Term Dialysis Compared with the General Population. Am. J. Kidney Dis. 59 (6), 819–828. doi:10.1053/j.ajkd.2011.12.023
Novotna, A., Srovnalova, A., Svecarova, M., Korhonova, M., Bartonkova, I., and Dvorak, Z. (2014). Differential Effects of Omeprazole and Lansoprazole Enantiomers on Aryl Hydrocarbon Receptor in Human Hepatocytes and Cell Lines. PLoS One 9 (6), e98711. doi:10.1371/journal.pone.0098711
Nunes, I., Gleizes, P. E., Metz, C. N., and Rifkin, D. B. (1997). Latent Transforming Growth Factor-Beta Binding Protein Domains Involved in Activation and Transglutaminase-dependent Cross-Linking of Latent Transforming Growth Factor-Beta. J. Cel Biol 136 (5), 1151–1163. doi:10.1083/jcb.136.5.1151
O'Neill, S., Humphries, D., Tse, G., Marson, L. P., Dhaliwal, K., Hughes, J., et al. (2015). Heat Shock Protein 90 Inhibition Abrogates TLR4-Mediated NF-Κb Activity and Reduces Renal Ischemia-Reperfusion Injury. Sci. Rep. 5, 12958. doi:10.1038/srep12958
Oeckinghaus, A., and Ghosh, S. (2009). The NF-kappaB Family of Transcription Factors and its Regulation. Cold Spring Harb Perspect. Biol. 1 (4), a000034. doi:10.1101/cshperspect.a000034
Pak, E. S., Uddin, M. J., and Ha, H. (2020). Inhibition of Src Family Kinases Ameliorates LPS-Induced Acute Kidney Injury and Mitochondrial Dysfunction in Mice. Int. J. Mol. Sci. 21 (21). doi:10.3390/ijms21218246
Panizo, S., Martínez-Arias, L., Alonso-Montes, C., Cannata, P., Martín-Carro, B., Fernández-Martín, J. L., et al. (2021). Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences. Int. J. Mol. Sci. 22 (1). doi:10.3390/ijms22010408
Pappas, B., Yang, Y., Wang, Y., Kim, K., Chung, H. J., Cheung, M., et al. (2018). p23 Protects the Human Aryl Hydrocarbon Receptor from Degradation via a Heat Shock Protein 90-independent Mechanism. Biochem. Pharmacol. 152, 34–44. doi:10.1016/j.bcp.2018.03.015
Park, J. S., Kim, S., Jo, C. H., Oh, I. H., and Kim, G. H. (2014). Effects of Dietary Salt Restriction on Renal Progression and Interstitial Fibrosis in Adriamycin Nephrosis. Kidney Blood Press. Res. 39 (1), 86–96. doi:10.1159/000355782
Perdew, G. H., Hollingshead, B. D., Dinatale, B. C., Morales, J. L., Labrecque, M. P., Takhar, M. K., et al. (2010). Estrogen Receptor Expression Is Required for Low-Dose Resveratrol-Mediated Repression of Aryl Hydrocarbon Receptor Activity. J. Pharmacol. Exp. Ther. 335 (2), 273–283. doi:10.1124/jpet.110.170654
Peters, J. M., Narotsky, M. G., Elizondo, G., Fernandez-Salguero, P. M., Gonzalez, F. J., and Abbott, B. D. (1999). Amelioration of TCDD-Induced Teratogenesis in Aryl Hydrocarbon Receptor (AhR)-Null Mice. Toxicol. Sci. 47 (1), 86–92. doi:10.1093/toxsci/47.1.86
Phang-Lyn, S., and Llerena, V. A. (2021). “Biochemistry, Biotransformation,” in StatPearls. (Treasure Island (FL)).
Poggio, E. D., Augustine, J. J., Arrigain, S., Brennan, D. C., and Schold, J. D. (2021). Long‐term Kidney Transplant Graft Survival-Making Progress when Most Needed. Am. J. Transpl. 21, 2824–2832. doi:10.1111/ajt.16463
Poormasjedi-Meibod, M. S., Salimi Elizei, S., Leung, V., Baradar Jalili, R., Ko, F., and Ghahary, A. (2016). Kynurenine Modulates MMP-1 and Type-I Collagen Expression via Aryl Hydrocarbon Receptor Activation in Dermal Fibroblasts. J. Cel Physiol 231 (12), 2749–2760. doi:10.1002/jcp.25383
Popolo, A., Pinto, A., Daglia, M., Nabavi, S. F., Farooqi, A. A., and Rastrelli, L. (2017). Two Likely Targets for the Anti-cancer Effect of Indole Derivatives from Cruciferous Vegetables: PI3K/Akt/mTOR Signalling Pathway and the Aryl Hydrocarbon Receptor. Semin. Cancer Biol. 46, 132–137. doi:10.1016/j.semcancer.2017.06.002
Powell, E., Wang, Y., Shapiro, D. J., and Xu, W. (2010). Differential Requirements of Hsp90 and DNA for the Formation of Estrogen Receptor Homodimers and Heterodimers. J. Biol. Chem. 285 (21), 16125–16134. doi:10.1074/jbc.M110.104356
Poyan Mehr, A., Tran, M. T., Ralto, K. M., Leaf, D. E., Washco, V., Messmer, J., et al. (2018). De Novo NAD+ Biosynthetic Impairment in Acute Kidney Injury in Humans. Nat. Med. 24 (9), 1351–1359. doi:10.1038/s41591-018-0138-z
Puyskens, A., Stinn, A., van der Vaart, M., Kreuchwig, A., Protze, J., Pei, G., et al. (2020). Aryl Hydrocarbon Receptor Modulation by Tuberculosis Drugs Impairs Host Defense and Treatment Outcomes. Cell Host Microbe 27 (2), 238–e7. doi:10.1016/j.chom.2019.12.005
Raghu, G., Johnson, W. C., Lockhart, D., and Mageto, Y. (1999). Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone: Results of a Prospective, Open-Label Phase II Study. Am. J. Respir. Crit. Care Med. 159 (4 Pt 1), 1061–1069. doi:10.1164/ajrccm.159.4.9805017
Raines, N. H., Ganatra, S., Nissaisorakarn, P., Pandit, A., Morales, A., Asnani, A., et al. (2021). Niacinamide May Be Associated with Improved Outcomes in COVID-19-Related Acute Kidney Injury: An Observational Study. Kidney360 2 (1), 33–41. doi:10.34067/KID.0006452020
Ralto, K. M., Rhee, E. P., and Parikh, S. M. (2020). NAD+ Homeostasis in Renal Health and Disease. Nat. Rev. Nephrol. 16 (2), 99–111. doi:10.1038/s41581-019-0216-6
Rannug, A., and Rannug, U. (2018). The Tryptophan Derivative 6-Formylindolo[3,2-B]carbazole, FICZ, a Dynamic Mediator of Endogenous Aryl Hydrocarbon Receptor Signaling, Balances Cell Growth and Differentiation. Crit. Rev. Toxicol. 48 (7), 555–574. doi:10.1080/10408444.2018.1493086
Romacho, T., Sánchez-Ferrer, C. F., and Peiró, C. (2013). Visfatin/Nampt: an Adipokine with Cardiovascular Impact. Mediators Inflamm. 2013, 946427. doi:10.1155/2013/946427
Ruiz-Ortega, M., Rayego-Mateos, S., Lamas, S., Ortiz, A., and Rodrigues-Diez, R. R. (2020). Targeting the Progression of Chronic Kidney Disease. Nat. Rev. Nephrol. 16 (5), 269–288. doi:10.1038/s41581-019-0248-y
Sabbatini, A. R., and Kararigas, G. (2020). Estrogen-related Mechanisms in Sex Differences of Hypertension and Target Organ Damage. Biol. Sex. Differ. 11 (1), 31. doi:10.1186/s13293-020-00306-7
Sanderson, D. J., and Cohen, M. S. (2020). Mechanisms Governing PARP Expression, Localization, and Activity in Cells. Crit. Rev. Biochem. Mol. Biol. 55 (6), 541–554. doi:10.1080/10409238.2020.1818686
Sanjabi, S., Oh, S. A., and Li, M. O. (2017). Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection. Cold Spring Harb Perspect. Biol. 9 (6). doi:10.1101/cshperspect.a022236
Schefold, J. C., Zeden, J. P., Fotopoulou, C., von Haehling, S., Pschowski, R., Hasper, D., et al. (2009). Increased Indoleamine 2,3-dioxygenase (Ido) Activity and Elevated Serum Levels of Tryptophan Catabolites in Patients with Chronic Kidney Disease: a Possible Link between Chronic Inflammation and Uraemic Symptoms. Nephrol. Dial. Transpl. 24 (6), 1901–1908. doi:10.1093/ndt/gfn739
Schroeder, J. C., Dinatale, B. C., Murray, I. A., Flaveny, C. A., Liu, Q., Laurenzana, E. M., et al. (2010). The Uremic Toxin 3-indoxyl Sulfate Is a Potent Endogenous Agonist for the Human Aryl Hydrocarbon Receptor. Biochemistry 49 (2), 393–400. doi:10.1021/bi901786x
Semenza, G. L., Jiang, B. H., Leung, S. W., Passantino, R., Concordet, J. P., Maire, P., et al. (1996). Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-Inducible Factor 1. J. Biol. Chem. 271 (51), 32529–32537. doi:10.1074/jbc.271.51.32529
Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., et al. (2011). Pirfenidone for Diabetic Nephropathy. J. Am. Soc. Nephrol. 22 (6), 1144–1151. doi:10.1681/ASN.2010101049
Shi, Y., Tang, B., Yu, J., Luo, Y., Xiao, Y., Pi, Z., et al. (2020). Aryl Hydrocarbon Receptor Signaling Activation in Systemic Sclerosis Attenuates Collagen Production and Is a Potential Antifibrotic Target. Int. Immunopharmacol 88, 106886. doi:10.1016/j.intimp.2020.106886
Shima, H., Sasaki, K., Suzuki, T., Mukawa, C., Obara, T., Oba, Y., et al. (2017). A Novel Indole Compound MA-35 Attenuates Renal Fibrosis by Inhibiting Both TNF-α and TGF-Β1 Pathways. Sci. Rep. 7 (1), 1884. doi:10.1038/s41598-017-01702-7
Shimizu, Y., Nakatsuru, Y., Ichinose, M., Takahashi, Y., Kume, H., Mimura, J., et al. (2000). Benzo[a]pyrene Carcinogenicity Is Lost in Mice Lacking the Aryl Hydrocarbon Receptor. Proc. Natl. Acad. Sci. U S A. 97 (2), 779–782. doi:10.1073/pnas.97.2.779
Soshilov, A., and Denison, M. S. (2011). Ligand Displaces Heat Shock Protein 90 from Overlapping Binding Sites within the Aryl Hydrocarbon Receptor Ligand-Binding Domain. J. Biol. Chem. 286 (40), 35275–35282. doi:10.1074/jbc.M111.246439
Stenström, M., Nyhlén, H. C., Törngren, M., Liberg, D., Sparre, B., Tuvesson, H., et al. (2016). Paquinimod Reduces Skin Fibrosis in Tight Skin 1 Mice, an Experimental Model of Systemic Sclerosis. J. Dermatol. Sci. 83 (1), 52–59. doi:10.1016/j.jdermsci.2016.04.006
Stenvinkel, P., Chertow, G. M., Devarajan, P., Levin, A., Andreoli, S. P., Bangalore, S., et al. (2021). Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2. Kidney Int. Rep. 6 (7), 1775–1787. doi:10.1016/j.ekir.2021.04.023
Sun, D., Xie, N., Wang, X., Wu, W., Li, X. Y., Chen, X., et al. (2021a). Serum RelB Is Correlated with Renal Fibrosis and Predicts Chronic Kidney Disease Progression. Clin. Transl Med. 11 (5), e362. doi:10.1002/ctm2.362
Sun, T., Huang, Z., Liang, W. C., Yin, J., Lin, W. Y., Wu, J., et al. (2021b). TGFβ2 and TGFβ3 Isoforms Drive Fibrotic Disease Pathogenesis. Sci. Transl Med. 13 (605). doi:10.1126/scitranslmed.abe0407
Sun, X., Chen, E., Dong, R., Chen, W., and Hu, Y. (2015). Nuclear Factor (NF)-κB P65 Regulates Differentiation of Human and Mouse Lung Fibroblasts Mediated by TGF-β. Life Sci. 122, 8–14. doi:10.1016/j.lfs.2014.11.033
Sun, X., Sun, B. L., Babicheva, A., Vanderpool, R., Oita, R. C., Casanova, N., et al. (2020). Direct Extracellular NAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling. Transcriptional Regulation by SOX and HIF-2α. Am. J. Respir. Cel Mol Biol 63 (1), 92–103. doi:10.1165/rcmb.2019-0164OC
Suzuki, T., Yamaguchi, H., Kikusato, M., Hashizume, O., Nagatoishi, S., Matsuo, A., et al. (2016). Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage. J. Am. Soc. Nephrol. 27 (7), 1925–1932. doi:10.1681/ASN.2015060623
Tao, S., Guo, F., Ren, Q., Liu, J., Wei, T., Li, L., et al. (2021). Activation of Aryl Hydrocarbon Receptor by 6-Formylindolo[3,2-B]carbazole Alleviated Acute Kidney Injury by Repressing Inflammation and Apoptosis. J. Cel Mol Med 25 (2), 1035–1047. doi:10.1111/jcmm.16168
Thackaberry, E. A., Gabaldon, D. M., Walker, M. K., and Smith, S. M. (2002). Aryl Hydrocarbon Receptor Null Mice Develop Cardiac Hypertrophy and Increased Hypoxia-Inducible Factor-1alpha in the Absence of Cardiac Hypoxia. Cardiovasc. Toxicol. 2 (4), 263–274. doi:10.1385/ct:2:4:263
Tsai, M. J., Hsu, Y. L., Wang, T. N., Wu, L. Y., Lien, C. T., Hung, C. H., et al. (2014). Aryl Hydrocarbon Receptor (AhR) Agonists Increase Airway Epithelial Matrix Metalloproteinase Activity. J. Mol. Med. (Berl) 92 (6), 615–628. doi:10.1007/s00109-014-1121-x
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., et al. (2021). SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am. J. Kidney Dis. 77 (1), 94–109. doi:10.1053/j.ajkd.2020.08.003
van den Born, B. J., Honnebier, U. P., Koopmans, R. P., and van Montfrans, G. A. (2005). Microangiopathic Hemolysis and Renal Failure in Malignant Hypertension. Hypertension 45 (2), 246–251. doi:10.1161/01.HYP.0000151620.17905.ee
Vaziri, C., Schneider, A., Sherr, D. H., and Faller, D. V. (1996). Expression of the Aryl Hydrocarbon Receptor Is Regulated by Serum and Mitogenic Growth Factors in Murine 3T3 Fibroblasts. J. Biol. Chem. 271 (42), 25921–25927. doi:10.1074/jbc.271.42.25921
Vogel, C. F., Sciullo, E., Li, W., Wong, P., Lazennec, G., and Matsumura, F. (2007). RelB, a New Partner of Aryl Hydrocarbon Receptor-Mediated Transcription. Mol. Endocrinol. 21 (12), 2941–2955. doi:10.1210/me.2007-0211
Walker, J. A., Richards, S., Belghasem, M. E., Arinze, N., Yoo, S. B., Tashjian, J. Y., et al. (2020). Temporal and Tissue-specific Activation of Aryl Hydrocarbon Receptor in Discrete Mouse Models of Kidney Disease. Kidney Int. 97 (3), 538–550. doi:10.1016/j.kint.2019.09.029
Wang, W., Hao, G., Pan, Y., Ma, S., Yang, T., Shi, P., et al. (2019). Serum Indoxyl Sulfate Is Associated with Mortality in Hospital-Acquired Acute Kidney Injury: a Prospective Cohort Study. BMC Nephrol. 20 (1), 57. doi:10.1186/s12882-019-1238-9
Wang, X., Hawkins, B. T., and Miller, D. S. (2011). Aryl Hydrocarbon Receptor-Mediated Up-Regulation of ATP-Driven Xenobiotic Efflux Transporters at the Blood-Brain Barrier. FASEB J. 25 (2), 644–652. doi:10.1096/fj.10-169227
Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., et al. (2021). Effects of Dapagliflozin on Major Adverse Kidney and Cardiovascular Events in Patients with Diabetic and Non-diabetic Chronic Kidney Disease: a Prespecified Analysis from the DAPA-CKD Trial. Lancet Diabetes Endocrinol. 9 (1), 22–31. doi:10.1016/S2213-8587(20)30369-7
Woeller, C. F., Roztocil, E., Hammond, C. L., Feldon, S. E., and Phipps, R. P. (2016). The Aryl Hydrocarbon Receptor and its Ligands Inhibit Myofibroblast Formation and Activation: Implications for Thyroid Eye Disease. Am. J. Pathol. 186 (12), 3189–3202. doi:10.1016/j.ajpath.2016.08.017
Wolf, G. (2005). Role of Reactive Oxygen Species in Angiotensin II-Mediated Renal Growth, Differentiation, and Apoptosis. Antioxid. Redox Signal. 7 (9-10), 1337–1345. doi:10.1089/ars.2005.7.1337
Wu, H. T., Lin, S. H., and Chen, Y. H. (2005). Inhibition of Cell Proliferation and In Vitro Markers of Angiogenesis by Indole-3-Carbinol, a Major Indole Metabolite Present in Cruciferous Vegetables. J. Agric. Food Chem. 53 (13), 5164–5169. doi:10.1021/jf050034w
Wu, M. H., Lin, C. N., Chiu, D. T., and Chen, S. T. (2020). Kynurenine/Tryptophan Ratio Predicts Angiotensin Receptor Blocker Responsiveness in Patients with Diabetic Kidney Disease. Diagnostics (Basel) 10 (4). doi:10.3390/diagnostics10040207
Xia, Y., Chen, S., Wang, Y., Mackman, N., Ku, G., Lo, D., et al. (1999). RelB Modulation of IkappaBalpha Stability as a Mechanism of Transcription Suppression of Interleukin-1alpha (IL-1alpha), IL-1beta, and Tumor Necrosis Factor Alpha in Fibroblasts. Mol. Cel Biol 19 (11), 7688–7696. doi:10.1128/MCB.19.11.7688
Xie, G., Peng, Z., and Raufman, J. P. (2012). Src-mediated Aryl Hydrocarbon and Epidermal Growth Factor Receptor Cross Talk Stimulates colon Cancer Cell Proliferation. Am. J. Physiol. Gastrointest. Liver Physiol. 302 (9), G1006–G1015. doi:10.1152/ajpgi.00427.2011
Xie, T., Bao, M., Zhang, P., Jiao, X., Zou, J., Ding, X., et al. (2019). Serum Concentration of Indoxyl Sulfate in Peritoneal Dialysis Patients and Low-Flux Hemodialysis Patients. Blood Purif. 48 (2), 183–190. doi:10.1159/000499749
Xing, D., Oparil, S., Yu, H., Gong, K., Feng, W., Black, J., et al. (2012). Estrogen Modulates NFκB Signaling by Enhancing IκBα Levels and Blocking P65 Binding at the Promoters of Inflammatory Genes via Estrogen Receptor-β. PLoS One 7 (6), e36890. doi:10.1371/journal.pone.0036890
Ye, L., Pang, W., Huang, Y., Wu, H., Huang, X., Liu, J., et al. (2021). Lansoprazole Promotes Cisplatin-Induced Acute Kidney Injury via Enhancing Tubular Necroptosis. J. Cel Mol Med 25 (5), 2703–2713. doi:10.1111/jcmm.16302
Yeh, Y. C., Huang, M. F., Liang, S. S., Hwang, S. J., Tsai, J. C., Liu, T. L., et al. (2016). Indoxyl Sulfate, Not P-Cresyl Sulfate, Is Associated with Cognitive Impairment in Early-Stage Chronic Kidney Disease. Neurotoxicology 53, 148–152. doi:10.1016/j.neuro.2016.01.006
Yisireyili, M., Takeshita, K., Saito, S., Murohara, T., and Niwa, T. (2017). Indole-3-propionic Acid Suppresses Indoxyl Sulfate-Induced Expression of Fibrotic and Inflammatory Genes in Proximal Tubular Cells. Nagoya J. Med. Sci. 79 (4), 477–486. doi:10.18999/nagjms.79.4.477
Yueh, M. F., Bonzo, J. A., and Tukey, R. H. (2005). The Role of Ah Receptor in Induction of Human UDP-Glucuronosyltransferase 1A1. Methods Enzymol. 400, 75–91. doi:10.1016/S0076-6879(05)00005-4
Zanger, U. M., and Schwab, M. (2013). Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation. Pharmacol. Ther. 138 (1), 103–141. doi:10.1016/j.pharmthera.2012.12.007
Zhang, L., Cao, J., Dong, L., and Lin, H. (2020a). TiPARP Forms Nuclear Condensates to Degrade HIF-1α and Suppress Tumorigenesis. Proc. Natl. Acad. Sci. U S A. 117 (24), 13447–13456. doi:10.1073/pnas.1921815117
Zhang, N., Agbor, L. N., Scott, J. A., Zalobowski, T., Elased, K. M., Trujillo, A., et al. (2010). An Activated Renin-Angiotensin System Maintains normal Blood Pressure in Aryl Hydrocarbon Receptor Heterozygous Mice but Not in Null Mice. Biochem. Pharmacol. 80 (2), 197–204. doi:10.1016/j.bcp.2010.03.023
Zhang, X. Q., Li, X., Zhou, W. Q., Liu, X., Huang, J. L., Zhang, Y. Y., et al. (2020b). Serum Lysyl Oxidase Is a Potential Diagnostic Biomarker for Kidney Fibrosis. Am. J. Nephrol. 51 (11), 1–12. doi:10.1159/000509381
Zhang, Y. Y., Yu, Y., and Yu, C. (2019). Antifibrotic Roles of RAAS Blockers: Update. Adv. Exp. Med. Biol. 1165, 671–691. doi:10.1007/978-981-13-8871-2_33
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., and Liu, F. F. (2020). Targeting Metabolic Dysregulation for Fibrosis Therapy. Nat. Rev. Drug Discov. 19 (1), 57–75. doi:10.1038/s41573-019-0040-5
Zhu, J., Luo, L., Tian, L., Yin, S., Ma, X., Cheng, S., et al. (2018). Aryl Hydrocarbon Receptor Promotes IL-10 Expression in Inflammatory Macrophages through Src-STAT3 Signaling Pathway. Front. Immunol. 9, 2033. doi:10.3389/fimmu.2018.02033
Keywords: RAAS, aryl hydrocarbon (Ah) receptor, kynurenine, hypoxia, PPAR γ, TGF—β1
Citation: Curran CS and Kopp JB (2022) Aryl Hydrocarbon Receptor Mechanisms Affecting Chronic Kidney Disease. Front. Pharmacol. 13:782199. doi: 10.3389/fphar.2022.782199
Received: 24 September 2021; Accepted: 14 January 2022;
Published: 14 February 2022.
Edited by:
Matthew Griffin, National University of Ireland Galway, IrelandReviewed by:
Naoka Murakami, Brigham and Women’s Hospital and Harvard Medical School, United StatesXiaoxin Wang, Georgetown University Medical Center, United States
Copyright © 2022 Curran and Kopp. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Colleen S. Curran, colleen.curran@nih.gov